valine has been researched along with bms-790052 in 669 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 567 (84.75) | 24.3611 |
| 2020's | 102 (15.25) | 2.80 |
| Authors | Studies |
|---|---|
| Belema, M; Chien, C; Colonno, RJ; Fridell, RA; Gao, M; Grasela, DM; Hamann, LG; Knipe, JO; Langley, DR; Lemm, JA; Meanwell, NA; Nettles, RE; Nguyen, VN; O'Boyle, DR; Serrano-Wu, MH; Snyder, LB; Sun, JH; Wang, C | 1 |
| Fridell, RA; Gao, M; Qiu, D; Valera, L; Wang, C | 1 |
| Bukh, J; Gottwein, JM; Jensen, TB; Mikkelsen, LS; Scheel, TK | 1 |
| Schmitz, J | 1 |
| Brain, P; Graham, EJ; Jones, LH; Lavender, H; Middleton, J; Palmer, A; Pickford, C; Pryde, D; Shaw, SM; Stammen, B; Targett-Adams, P; Tran, TD; Wakenhut, F; Westby, M | 1 |
| Elazar, M; Glenn, JS; Hang, JQ; Klumpp, K; Lee, C; Leveque, V; Ma, H; Sklan, EH | 1 |
| Alberts, J; Cantone, JL; Gao, M; Huang, XS; Leet, JE; Lemm, JA; Martin, SW; Meanwell, NA; Nower, PT; O'Boyle, DR; Romine, JL; Schroeder, DR; Serrano-Wu, MH; Snyder, LB; Sun, JH | 1 |
| Fridell, RA; Gao, M; Qiu, D; Rose, RE; Valera, L; Wang, C | 1 |
| Kato, T; Masaki, T; Munakata, T; Murayama, A; Nakamoto, S; Nomoto, A; Okamoto, Y; Wakita, T; Watanabe, H; Yokosuka, O | 1 |
| Arnold, ME; Deng, Y; Jemal, M; Jiang, H; Ouyang, Z; Salcedo, TW; Xia, YQ; Zeng, J | 1 |
| Bifano, M; Fridell, RA; Gao, M; Huang, X; Kienzle, B; Nettles, RE; Nower, P; O'Boyle, DR; Qiu, D; Roberts, S; Sun, JH; Valera, L; Wang, C | 1 |
| Bifano, M; Chung, E; DeMicco, MP; Fuentes, E; Gao, M; Goldwater, R; Grasela, DM; Lawitz, E; Lopez-Talavera, JC; Marbury, TC; Nettles, RE; Persson, A; Rodriguez-Torres, M; Vutikullird, A | 1 |
| Gish, RG; Meanwell, NA | 1 |
| Lee, C | 2 |
| Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H | 1 |
| Dieterich, D | 1 |
| Fridell, RA; Gao, M; Huang, H; Huang, X; Jia, L; Nower, PT; O'Boyle, DR; Qiu, D; Sun, JH; Valera, L; Wang, C | 1 |
| Ferenci, P | 1 |
| Fridell, RA; Gao, M; Nettles, RE; Nower, P; O'Boyle Ii, DR; Roberts, S; Sun, JH; Valera, L; Wang, C; Zhang, Y | 1 |
| Dimitrova, DI; Eley, T; Everson, GT; Gardiner, DF; Ghalib, R; Grasela, DM; Guo, T; Lawitz, E; Lok, AS; Martorell, C; McPhee, F; Pasquinelli, C; Persson, A; Reindollar, R; Rustgi, V; Wind-Rotolo, M; Zhu, K | 1 |
| Chung, RT | 1 |
| Barreiro, P; del Mar Gonzalez, M; Plaza, Z; Poveda, E; Seclén, E; Soriano, V; Vispo, E | 1 |
| Gao, M; Lin, K; Liu, Q; Villareal, VA; Yang, PL | 1 |
| Arnold, ME; Aubry, AF; Bifano, M; Burrell, R; Dockens, R; Easter, J; Gu, H; Jiang, H; Wang, J; Wang, JS; Zeng, J | 1 |
| Arnold, ME; Bifano, M; Cojocaru, L; Jiang, H; Kandoussi, H; Liu, Y; Ryan, J; Wang, X; Zeng, J | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Miyakawa, Y; Saito, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA | 1 |
| Welzel, TM; Zeuzem, S | 1 |
| Abrams, GA; Bräu, N; Bronowicki, JP; Diva, U; Everson, GT; Ghalib, RH; Hernandez, D; Hézode, C; Hindes, R; Hughes, EA; Lim, JK; Martorell, C; McPhee, F; Morris, DW; Pol, S; Reindollar, RW; Rustgi, VK; Schnittman, S; Tatum, HA; Thuluvath, PJ; Wind-Rotolo, M; Yin, PD | 1 |
| Cameron, CE; Chatterji, U; Cordek, D; Gallay, PA; Garcia-Rivera, JA; Lim, PJ; Lin, K; Sharma, SD; Targett-Adams, P | 1 |
| Gao, M; Lemm, JA; Liu, M; Pelosi, LA; Voss, S | 1 |
| Belema, M; Gao, M; Goodrich, J; Kakarla, R; Knipe, JO; Lemm, JA; Liu, M; Lopez, OD; Meanwell, NA; Nguyen, VN; Nower, PT; O'Boyle, D; Qiu, Y; Romine, JL; Serrano-Wu, MH; Snyder, LB; St Laurent, DR; Sun, JH; Valera, L; Yang, F; Yang, X | 1 |
| Fridell, RA; Gao, M; Jia, L; Kirk, MJ; Valera, L; Wang, C | 1 |
| Barreiro, P; Fernández-Montero, JV; Poveda, E; Soriano, V; Vispo, E | 1 |
| Arnold, ME; Aubry, AF; Bifano, M; Burrell, R; Easter, J; Gu, H; Jiang, H; Kandoussi, H; Li, W; Titsch, C; Zeng, J | 1 |
| Sheridan, C | 1 |
| Chatterjee, A; Perelson, AS; Smith, PF | 1 |
| Suk-Fong Lok, A | 1 |
| Chayama, K; Hernandez, D; Ikeda, K; Ishikawa, H; Karino, Y; Kawakami, Y; Kumada, H; McPhee, F; Suzuki, F; Toyota, J; Watanabe, H; Yu, F | 1 |
| Chayama, K; Eley, T; Hu, W; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kawakami, Y; Kumada, H; McPhee, F; Suzuki, F; Suzuki, Y; Toyota, J; Watanabe, H | 1 |
| Alisi, A; Comparcola, D; Della Corte, C; Nobili, V; Sartorelli, MR | 1 |
| Belema, M; Fridell, RA; Gao, M; Good, AC; Goodrich, JT; Lemm, JA; Liu, M; Lopez, OD; Meanwell, NA; Nguyen, VN; Nower, PT; O'Boyle, DR; Qiu, Y; Ripka, AS; Serrano-Wu, MH; Snyder, LB; St Laurent, DR; Sun, JH; Valera, L; Yang, F | 1 |
| Bukh, J; Ghanem, L; Gottwein, JM; Jensen, SB; Li, YP; Mikkelsen, L; Scheel, TK; Serre, SB | 1 |
| Chaniewski, S; Chen, C; Friborg, J; Lemm, JA; Levine, S; McPhee, F; Sheaffer, AK; Voss, S | 1 |
| Forns, X; Lens, S; Londoño, MC | 1 |
| Hernandez, D; McPhee, F; Monikowski, A; Ueland, J; Zhou, N | 1 |
| Fridell, RA; Gao, M; Nower, P; O'Boyle, DR; Roberts, S; Sun, JH; Valera, L; Wang, C | 1 |
| Cotler, SJ; Dahari, H; Guedj, J; Layden, TJ; Nettles, RE; Perelson, AS; Rong, L; Sansone, ND; Uprichard, SL | 1 |
| Amblard, F; Bobeck, DR; Chavre, S; Coats, SJ; McBrayer, TR; Nettles, JH; Schinazi, RF; Shi, J; Tharnish, P; Whitaker, T; Zhang, H; Zhou, L | 1 |
| Carifa, A; Eley, T; Falk, P; Fridell, R; Gardiner, D; Hernandez, D; McPhee, F; Monikowski, A; Ueland, J; Wang, C; Yu, F; Zhou, N | 1 |
| Pawlotsky, JM | 1 |
| Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA; Symonds, WT | 1 |
| Fridell, R; Gao, M; Nower, PT; O'Boyle, DR; Sun, JH; Valera, L; Wang, C | 1 |
| Aghemo, A; Colombo, M | 1 |
| Beran, RK; Bush, CO; Delaney, WE; Greenstein, AE | 1 |
| Dahari, H; Guedj, J; Perelson, AS; Uprichard, SL | 1 |
| Herbst, DA; Reddy, KR | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Ke, R; Lloyd-Smith, JO; Loverdo, C; Olson, CA; Qi, H; Sun, R; Wu, NC | 1 |
| Bourlière, M; Chung, E; Eley, T; Everson, GT; Gardiner, DF; Grasela, DM; Hézode, C; Huang, SP; Lawitz, E; Loustaud-Ratti, V; Marcellin, P; McPhee, F; Pasquinelli, C; Pol, S; Rodriguez-Torres, M; Rustgi, V; Schwartz, H; Sims, KD; Tatum, H; Thuluvath, PJ; Wang, X; Wind-Rotolo, M | 1 |
| Bukh, J; Gottwein, JM; Humes, D; Jensen, SB; Li, YP; Ramirez, S | 1 |
| Friedman, SL | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hwang, C; Jiang, H; Kandoussi, H; Sevinsky, H | 1 |
| Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Coppola, N; Gentile, I | 1 |
| Corouge, M; Pol, S; Vallet-Pichard, A | 1 |
| Dieterich, DT; Martel-Laferrière, V | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Eley, T; Everson, GT; Gao, M; Gardiner, DF; Grasela, DM; Hassanein, T; Hernandez, D; Hindes, R; Hinestrosa, F; Huang, SP; Jacobson, I; Lawitz, E; Lok, AS; McPhee, F; Nelson, DR; Pasquinelli, C; Reddy, KR; Rodriguez-Torres, M; Schwartz, H; Sherman, D; Sulkowski, MS; Symonds, W; Thuluvath, PJ; Wind-Rotolo, M | 1 |
| Bourlière, M; Eley, T; Everson, GT; Gardiner, DF; Grasela, DM; Hézode, C; Huang, SP; Lawitz, EJ; Li, J; Lok, AS; Marcellin, P; McPhee, F; Pasquinelli, C; Pol, S; Rodriguez-Torres, M; Serfaty, L; Wind-Rotolo, M; Yu, F | 1 |
| Chayama, K; Hernandez, D; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Monikowski, A; Osaki, Y; Toyota, J; Ueland, J; Watanabe, H; Yokosuka, O; Yu, F; Zhou, N | 1 |
| Chayama, K; Hayashi, N; Hu, W; Hughes, EA; Ikeda, K; Ishikawa, H; Kumada, H; McPhee, F; Miyagoshi, H; Mochida, S; Suzuki, F; Toyota, J | 1 |
| Hu, W; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Osaki, Y; Sata, M; Ueki, T; Yamamoto, K; Yokosuka, O | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Honda, Y; Imamura, M; Inaba, T; Kanai, A; Kawaoka, T; Kosaka, K; Matsui, H; McPhee, F; Miki, D; Murakami, E; Ochi, H; Ono, A; Takahashi, S; Tsuge, M | 1 |
| Adams, SP; Bachand, C; Belema, M; Cantor, GH; Chimalakonda, A; Colonno, RJ; Deon, DH; Fridell, RA; Fura, A; Gao, M; Goodrich, JT; Hamann, LG; James, CA; Johnson, BM; Knipe, JO; Langley, DR; Lavoie, R; Lemm, JA; Lopez, OD; Martel, A; Meanwell, NA; Nguyen, VN; O'Boyle, DR; Parker, DD; Romine, JL; Ruediger, EH; Santone, KS; Snyder, LB; St Laurent, DR; Wong, HS; Yang, F; Zhu, J | 1 |
| Chayama, K; Damokosh, A; Eley, T; Hughes, E; Ido, A; Ikeda, K; Ishikawa, H; Izumi, N; Karino, Y; Kawada, N; Kawakami, Y; Koike, K; Kumada, H; McPhee, F; Miyagoshi, H; Sata, M; Suzuki, Y; Takaguchi, K; Takehara, T; Toyota, J; Yamamoto, K | 1 |
| Garcia-Diaz, A; Haque, T; Macartney, MJ; McCormick, AL; Wang, L; Webster, DP | 1 |
| Angell, R; Garnett, JA; Hedgethorne, K; Lambert, SM; Langley, DR; Matthews, SJ; Meanwell, NA | 1 |
| Kanda, T; Nakamoto, S; Shirasawa, H; Wu, S; Yokosuka, O | 1 |
| Al-Mawsawi, LQ; Chen, SH; Chen, Z; Chu, V; Du, Y; Ke, R; Lin, CY; Lloyd-Smith, JO; Loverdo, C; Olson, CA; Qi, H; Remenyi, R; Su, SY; Sun, R; Truong, S; Wu, NC; Wu, TT; Zhong, W | 1 |
| Anwar-Mohamed, A; Barakat, KH; Houghton, M; Robins, MJ; Tuszynski, JA; Tyrrell, DL | 1 |
| Pavri, TM; Reddy, KR; Sinese, L; Wirjosemito, A | 1 |
| Belema, M; Meanwell, NA | 1 |
| Barth, H; Baumert, TF; Bukh, J; Doffoël, M; Fofana, I; Habersetzer, F; Heydmann, L; Patel, AH; Soulier, E; Xiao, F; Zeisel, MB | 1 |
| Chiba, K; Fu, Z; Furihata, T; Kobayashi, K; Matsumoto, S; Sun, Y; Tsubota, A | 1 |
| Gallay, PA; Lim, PJ | 1 |
| Adler, H; Lambert, JS | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Fridell, RA; Gao, M; Huang, X; Jia, L; Kienzle, B; Nower, P; O'Boyle, DR; Rigat, K; Roberts, S; Sun, JH; Valera, L; Wang, C | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Inaba, T; Kanai, A; Kawaoka, T; Kosaka, K; Matsui, H; Miki, D; Murakami, E; Ochi, H; Tsuge, M; Yoshimi, S | 1 |
| Andreoli, A; Angelico, M; D'Offizi, G; Durand, C; Ferenci, P; Knop, V; Lenci, I; Lionetti, R; Montalbano, M; Pellicelli, AM; Telese, A; Zeuzem, S | 1 |
| Bartenschlager, R; Berger, C; Gao, M; Harak, C; Hoppe, S; Lohmann, V; Paul, D; Penin, F; Radujkovic, D; Romero-Brey, I; Terreux, R; Zayas, M | 1 |
| Izumi, N | 1 |
| Bourliere, M; Bronowicki, JP; Chang, TT; Chu, CJ; Everson, GT; Gerken, G; Gordon, SC; Heo, J; Hughes, E; Jacobson, IM; Kao, JH; Kopit, J; Lee, YJ; Linaberry, M; Manns, M; Marcellin, P; McPhee, F; Mendez, P; Metivier, S; Noviello, S; Peng, CY; Pol, S; Sievert, W; Thabut, D; Towner, WJ; Yoffe, B | 1 |
| Gane, E | 1 |
| Bourlière, M; Bräu, N; Brunetto, MR; Esmat, G; Everson, GT; Fried, MW; Ghesquiere, W; Hernandez, D; Hézode, C; Hirschfield, GM; Hughes, EA; Kwo, PY; Lawitz, EJ; Liu, Z; McPhee, F; Noviello, S; Pockros, PJ; Pol, S; Rodriguez-Torres, M; Rustgi, VK; Schnittman, S; Serfaty, L; Shafran, SD; Sievert, W; Sulkowski, M; Tatum, HA; Thuluvath, PJ; Vierling, JM; Waked, I; Weiland, O; Weis, N; Wind-Rotolo, M; Yin, PD; Zeuzem, S | 1 |
| Bertz, R; Bifano, M; Eley, T; Gardiner, D; Grasela, DM; He, B; Huang, SP; Kandoussi, H; Sevinsky, H; Zhu, K | 1 |
| Poole, RM | 1 |
| Aghemo, A; De Francesco, R | 1 |
| Beard, MR; Eyre, NS | 1 |
| Buclin, T; Chtioui, H; Moradpour, D | 1 |
| Fujii, Y; Mochida, S; Uchida, Y | 1 |
| Brunetto, MR; Cohen, D; Cooney, E; de Lédinghen, V; Dore, GJ; Fung, SK; George, J; Ghesquiere, W; Hagens, P; Harley, H; Hernandez, D; Hézode, C; Hughes, EA; Larrey, D; Lawitz, E; Lee, SS; McPhee, F; Noviello, S; Pol, S; Ramji, A; Shafran, SD; Strasser, SI; Taliani, G; Tatum, HA; Tran, A; Weis, N; Zaltron, S | 1 |
| Amblard, F; Broyde, J; Coats, SJ; Kohler, JJ; McBrayer, TR; Nettles, JH; Schinazi, RF; Shi, J; Stanton, RA; Whitaker, T; Zhang, H; Zhou, L | 1 |
| Hodges, MR; Ottosen, S; Parsley, TB; Patick, AK; Raney, AK; van der Veer, E; van Doorn, LJ; Yang, L; Zeh, K | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Serfaty, L | 1 |
| Abdel-Razek, W; Waked, I | 1 |
| Nelson, DR; Peter, J | 1 |
| Berger, KL; Chukkapalli, V; Deiters, A; Kelly, SM; Randall, G; Thomas, M | 1 |
| Bennett, M; Chung, E; Gardiner, DF; Gitlin, N; Grasela, DM; Griffies, A; Hassanein, T; Lawitz, E; McPhee, F; Nguyen, T; Rege, B; Schwartz, H; Sims, KD; Thuluvath, PJ; Webster, L; Wind-Rotolo, M; Younossi, Z; Zhou, H; Zhou, N | 1 |
| Bennett, M; Bernstein, D; Cooper, JN; Freilich, BF; Ghalib, R; Gitlin, N; Harlan, W; Hawkins, T; Hennicken, D; Hughes, EA; Kowdley, KV; Lalezari, JP; Lawitz, E; McPhee, F; Nelson, DR; Oguchi, G; Ortiz-Lasanta, G; Pockros, PJ; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Thuluvath, PJ; Varunok, P; Younes, ZH | 1 |
| Alcorn, H; Bertz, R; Bifano, M; Garimella, T; Hwang, C; Kandoussi, H; Luo, WL; Marbury, TC; Sherman, D; Wang, R | 1 |
| Arnold, ME; Aubry, AF; Baker, C; Burrell, R; Cojocaru, L; Demers, R; Easter, J; Eley, T; He, B; Jiang, H; Kadiyala, P; Kandoussi, H; Pursley, J; Ryan, J; Wang, J; Zeng, J | 1 |
| Bernstein, D; Brunetto, M; de Ledinghen, V; Elkhashab, M; Everson, G; Hennicken, D; Heo, J; Hézode, C; Hughes, E; Jensen, D; Kugelmas, M; Luketic, V; Mauss, S; McPhee, F; Mendez, P; Noviello, S; Pol, S; Serfaty, L; Sherman, KE; Tran, A; Vierling, J; Younes, ZH; Zeuzem, S | 1 |
| McCormack, PL | 1 |
| Bertz, RJ; Bifano, M; Eley, T; Hiraoka, M; Nagashima, H; Shiozaki, T; Ueno, T; Yamahira, N | 1 |
| Suzuki, F | 2 |
| Chayama, K; Imamura, M | 1 |
| Amano, M; Ishikawa, H | 1 |
| Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH | 1 |
| Hirotsu, Y; Kanda, T; Matsumura, H; Moriyama, M; Omata, M; Yokosuka, O | 1 |
| Bartlett, C; Griffin, S; Harris, M; Ross-Thriepland, D; Shaw, J; Stewart, H | 1 |
| Hayward, P | 1 |
| Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 1 |
| Manns, MP; Wedemeyer, H; Zeuzem, S | 1 |
| Ji, J; Liu, D; Michailidis, E; Ndongwe, TP; Ralston, R; Rice, CM; Sarafianos, SG | 1 |
| Bondeson, K; Kjellin, M; Lannergard, A; Lennerstrand, J; Lindström, I; Palanisamy, N; Wesslén, L | 1 |
| Bartolini, B; Capobianchi, MR; D'Offizi, G; Garbuglia, AR; Gianpiero, D; Giombini, E; Hughes, EA; Ippolito, G; Lionetti, R; McPhee, F; Montalbano, M; Sias, C; Taibi, C; Zhou, N | 1 |
| Adamczyk, R; Bertz, RJ; Bifano, M; Hwang, C; Kandoussi, H; Marion, A | 1 |
| Conjeevaram, H | 1 |
| Angus, P; Bennett, M; Boparai, N; Boyer, N; Bräu, N; Bronowicki, JP; Conway, B; de Lédinghen, V; Hughes, E; Jacobson, I; Lee, SS; Levin, J; McPhee, F; Mollison, L; Muir, AJ; Ortiz-Lasanta, G; Pol, S; Poordad, F; Reddy, KR; Sepe, T; Sievert, W; Sulkowski, M; Swenson, ES; Tam, E; Tse, E; Yin, PD | 1 |
| Cooper, J; Dore, GJ; Everson, G; Freilich, B; Ghesquiere, W; Herring, R; Hézode, C; Hughes, EA; Kwo, P; Lalezari, J; McPhee, F; Muir, AJ; Pockros, PJ; Poordad, F; Ramji, A; Reau, N; Sheikh, A; Stuart, K; Swenson, ES; Thompson, AJ; Tran, A; Vierling, J; Yang, R; Yin, PD; Yozviak, J | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kawakami, Y; Murakami, E; Ochi, H; Sasaki, T; Tsuge, M; Yoshimi, S | 1 |
| Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M | 1 |
| Aboulker, JP; Bailly, F; Billaud, E; Bronowicki, JP; Diallo, A; Izopet, J; Lacombe, K; Meyer, L; Molina, JM; Paniez, H; Piroth, L; Rey, D; Rosenthal, E; Simony, M; Taburet, AM; Vincent, C; Zucman, D | 1 |
| Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A | 1 |
| Bunchorntavakul, C; Reddy, KR | 1 |
| Warpakowski, A | 2 |
| Halász, T; Horváth, G; Hunyady, B; Makara, M | 1 |
| Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C | 1 |
| Stingl, W | 1 |
| Daelemans, D; Delang, L; Grabner, M; Helsen, N; Neyts, J; Scheers, E; Vanstreels, E; Verfaillie, C; Verpaalen, B | 1 |
| Kmietowicz, Z | 1 |
| Cai, J; Chen, B; Chen, J; Ji, M; Li, W; Wang, P; Zhou, G; Zong, X | 1 |
| Rizza, SA; Temesgen, Z | 1 |
| Amblard, F; Boucle, S; Coats, SJ; Li, C; McBrayer, TR; Nettles, JH; Schinazi, RF; Stanton, RA; Tao, S; Whitaker, T | 1 |
| Dusheiko, G; Kalafateli, M; Manousou, P | 1 |
| Ikeda, F; Iwasaki, Y; Kinugasa, H; Matsubara, T; Mori, C; Shiraha, H; Takaguchi, K; Takaki, A; Toyooka, S; Yamamoto, K | 1 |
| Bertz, R; Bifano, M; Bruce, RD; DeMicco, M; Garimella, T; Hwang, C; Kandoussi, H; Luo, WL; Wang, R; Wastall, P | 1 |
| Ahn, SH; Bhore, R; Chayama, K; Hernandez, D; Ishikawa, H; Karino, Y; Kawakami, Y; Kumada, H; McPhee, F; Mendez, P; Suzuki, Y; Toyota, J; Yu, ML; Zhou, N | 1 |
| Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Behl, AS; Betts, KA; Kalsekar, A; Li, J; Signorovitch, JE; Song, Y; Sorg, RA | 1 |
| Hernandez, D; McPhee, F; Sims, K; Ueland, J; Yang, X; Yin, PD; Yu, F; Zhou, N | 1 |
| Beinhardt, S; Ferenci, P; Ferlitsch, A; Freissmuth, C; Hofer, H; Kozbial, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Schwarzer, R; Stättermayer, AF; Trauner, M | 1 |
| Ackerman, P; Dieterich, D; Dretler, R; Fishbein, D; Gathe, JC; Henn, S; Hinestrosa, F; Hughes, E; Huynh, C; Liu, Z; Luetkemeyer, A; McDonald, C; McPhee, F; Mills, A; Morgan, TR; Noviello, S; Overton, ET; Ramgopal, M; Rashbaum, B; Ray, G; Ruane, PJ; Scarsella, A; Sherman, KE; Sulkowski, MS; Wyles, DL; Yin, PD; Yozviak, J | 1 |
| Hikita, H; Hiramatsu, N; Kai, Y; Morishita, N; Nakabori, T; Nawa, T; Oze, T; Saito, Y; Sakamori, R; Suemizu, H; Takehara, T; Tanaka, S; Tatsumi, T; Yakushijin, T | 1 |
| Forns, X; Gambato, M; Lens, S; Mariño, Z | 1 |
| Boonstra, A; de Knegt, RJ; Hansen, BE; Hou, J; Janssen, HL; Kreefft, K; Spaan, M; van Oord, G | 1 |
| Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Manns, MP; Mix, C; Mix, H; Port, K; Solbach, P; Sollik, L; Wedemeyer, H; Worzala, D | 1 |
| Boor, PP; de Jonge, J; de Ruiter, PE; Ijzermans, JN; Kwekkeboom, J; Metselaar, HJ; Tilanus, HW; van der Laan, LJ | 1 |
| Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T | 1 |
| Algalarrondo, V; Antonini, T; Chaumais, MC; Duclos-Vallée, JC; Renet, S; Samuel, D; Savoure, A; Thomas, L; Zhao, A | 1 |
| Ueda, Y; Uemoto, S | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Gimeno-Ballester, V; Mar, J; San Miguel, R | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Scotto, R; Zappulo, E | 1 |
| Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Alkan, M; Balkan, II; Mete, B; Ozaras, R; Tabak, F; Yemisen, M | 1 |
| Clausznitzer, D; Harnisch, J; Kaderali, L | 1 |
| Bronowicki, JP; Hézode, C | 1 |
| Akamatsu, N; Kokudo, N; Sugawara, Y | 1 |
| Rao, HY; Wang, Y; Wei, L; Xie, XW | 1 |
| Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C | 1 |
| Goeree, R; Martel, MJ; Moshyk, A; Tahami Monfared, AA | 1 |
| Al-Assi, MT; Banyai, T; Beumont-Mauviel, M; Bifano, M; Boparai, N; Bourlière, M; Bronowicki, JP; Buti, M; Cheung, K; Gadano, A; Gea, F; Hézode, C; Hughes, EA; Loustaud-Ratti, V; Makara, M; McPhee, F; Noviello, S; Olveira, A; Ouwerkerk-Mahadevan, S; Petersen, J; Picchio, G; Pol, S; Pruitt, R; Thabut, D; Zeuzem, S | 1 |
| Hubbard, H; Lawitz, E; Vizuete, J | 1 |
| Desta, T; Eley, T; Everson, GT; Gardiner, DF; Gitlin, N; Grasela, DM; Hassanein, T; Hawkins, T; Hinestrosa, F; Huang, SP; Lawitz, E; Levin, JM; McPhee, F; Rodriguez-Torres, M; Rustgi, V; Schwartz, H; Sims, KD; Thuluvath, PJ; Webster, L; Younossi, Z | 1 |
| Burchill, MA; Golden-Mason, L; Rosen, HR; Wind-Rotolo, M | 1 |
| Mohammad, RA; Regal, RE; Smith, MA | 1 |
| Belema, M; Cockett, M; Fridell, RA; Gao, M; Hewawasam, P; Johnson, BM; Kadow, J; Kramer, M; Langley, DR; Lemm, JA; Liu, M; Meanwell, NA; Moulin, F; Nophsker, MJ; Nower, P; O'Boyle, DR; Rigat, K; Roberts, SB; Sun, JH; Tu, Y; Wang, C; Wang, YK | 1 |
| Kao, JH; Yang, SS | 1 |
| Espinoza, MA; Giglio, A; Soza, A; Vargas, CL | 1 |
| Bennett, H; Brenner, M; Gordon, J; Kalsekar, A; McEwan, P; Ward, T; Webster, S; Yuan, Y | 1 |
| Aghemo, A; Colombo, M; Degasperi, E | 1 |
| Kowdley, KV; Sundaram, V | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Miki, D; Miyaki, E; Ochi, H; Tateno, C; Tsuge, M; Uchida, T | 1 |
| Gordon, SC; Jafri, SM | 1 |
| Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y | 1 |
| Bessone, F; Bhore, R; Heo, J; Hughes, E; Jacobson, I; Jensen, DM; Kao, JH; Kumada, H; Lee, YJ; Manns, MP; Mendez, P; Noviello, S; Peng, CY; Roberts, SK; Sievert, W; Toyota, J; Yoffe, B | 1 |
| Belema, M; Cockett, M; Fridell, R; Gao, M; Hewawasam, P; Lopez, O; Meanwell, NA; Nower, PT; O'Boyle, DR; Roberts, SB; Sun, JH; Tu, Y; Wang, C | 1 |
| Ghany, M; Keane, M; Liang, TJ; O'Keefe, AC; Park, H; Rehermann, B; Rivera, E; Serti, E | 1 |
| Adie, SK; Rizza, SA; Temesgen, Z; Zeuli, JD | 1 |
| Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R | 1 |
| Aichelburg, MC; Bucsics, T; Chromy, D; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Stättermayer, AF; Steiner, S; Trauner, M | 1 |
| Furuya, K; Horimoto, H; Izumi, T; Kimura, M; Kobayashi, T; Konno, J; Kudo, M; Morikawa, K; Nagasaka, A; Nakai, M; Natsuizaka, M; Ogawa, K; Sakamoto, N; Sato, F; Shinada, K; Sho, T; Suda, G; Tateyama, M; Terashita, K; Tsukuda, Y; Tsunematsu, S; Umemura, M; Yamamoto, Y; Yamasaki, K | 1 |
| Arleo, A; Copetti, M; Mangia, A; Miscio, M; Piazzolla, V; Santoro, R; Squillante, MM | 1 |
| Kelley, C; McPhee, F; Signorovitch, J; Swallow, E; Wygant, G | 1 |
| Friedman, J; Hussar, DA | 1 |
| Angus, P; Bhore, R; Bronowicki, JP; Dore, GJ; Hezode, C; Jimenez-Exposito, MJ; Leroy, V; McPhee, F; Pianko, S; Pol, S; Stuart, K; Thompson, AJ; Tse, E | 1 |
| André, P; Burmeister, WP; Caporossi, A; François, O; Fusillier, K; Geneletti, L; Larrat, S; Leroy, V; Morand, P; Ramière, C; Santoni, E; Tarbouriech, N; Thélu, MA; Trémeaux, P | 1 |
| Ackerman, P; Kalsekar, A; Kelley, C; Mu, F; Peeples, M; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Bouvier-Alias, M; Chevaliez, S; Féray, C; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Iio, E; Ishikawa, T; Kumada, T; Tada, T; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsuji, K; Zeniya, M | 1 |
| Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O | 1 |
| Adachi, K; Ishii, T; Kumon, D; Matsumoto, N; Noguchi, Y; Okuse, C; Sato, A; Tamura, T | 1 |
| Araújo, ES; Bourliere, M; Canini, L; Chiche, L; Coquet, E; Cotler, SJ; Dahari, H; Graw, F; Halfon, P; Penaranda, G; Renou, C; Riso, A; Uprichard, SL | 1 |
| Ferriols-Lisart, R; Guglieri-López, B; Merino-Sanjuán, M; Pérez-Pitarch, A | 1 |
| Sankawa, Y | 1 |
| Benhaourech, S; Borentain, P; Bregigeon, S; Colson, P; Darque, A; Gaubert, MR; Habib, G; Laugier, D; Maille, B; Renard, S; Salaun, E | 1 |
| Bonacorsi, SJ; Burrell, RC; Easter, JA | 1 |
| Ackens, R; Posthouwer, D | 1 |
| Fukuda, Y; Hattori, N; Hiraishi, T; Ikeda, H; Ishii, T; Itoh, F; Matsumoto, N; Matsunaga, K; Noguchi, Y; Okuse, C; Sato, A; Shigefuku, R; Suzuki, M; Tamura, T; Watanabe, T | 1 |
| Bae, SH; Chen, X; Chuang, WL; Garimella, T; Gong, G; Jia, J; Jia, Z; Li, Y; Lin, S; Lu, W; McPhee, F; Mo, L; Niu, J; Torbeyns, A; Treitel, M; Wei, L; Xie, Q; Xie, W; Xu, M; Yang, YF; Yin, PD; Zhang, M | 1 |
| Ahn, SH; Bhore, R; Chang, TT; Heo, J; Hughes, E; Kao, JH; Lee, YJ; Lim, YS; Noviello, S; Peng, CY; Torbeyns, A | 1 |
| Abdurakhmanov, D; Baruch, Y; Bruck, R; Diago, M; Ferenci, P; Flisiak, R; Gadano, A; Hughes, EA; Jacobson, I; Janczewska, E; Knysz, B; Kopit, J; Lueth, S; McPhee, F; Michener, T; Noviello, S; Safadi, R; Shafran, S; Thabut, D; Thompson, AJ; Yin, PD; Zarebska-Michaluk, D; Zeuzem, S; Zignego, AL | 1 |
| Ackerman, P; Bhore, R; Luetkemeyer, AF; McDonald, C; Noviello, S; Ramgopal, M | 1 |
| Belema, M; Caceres-Cortes, J; Chang, SY; Easter, J; Fancher, RM; Gao, M; Goodrich, J; Hamann, LG; Hong, Y; Huang, X; Humphreys, WG; Johnson, BM; Leet, JE; Li, W; Liu, X; Lopez, OD; Ma, L; Nguyen, V; Shu, YZ; Zhao, W; Zhu, M | 1 |
| Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA | 1 |
| Miyagi, K; Miyazaki, R | 1 |
| Furuta, K; Kamada, T; Tomioka, H | 1 |
| Ferenci, P; Freissmuth, C; Graziadei, I; Gschwantler, M; Hametner, S; Hofer, H; Karpi, A; Kozbial, K; Laferl, H; Maieron, A; Moser, S; Ramona, AZ; Stauber, RE; Stern, R; Vogel, W; Zoller, HM | 1 |
| Burger, DM; D'Avolio, A; Di Perri, G; Drenth, JP; Grintjes, K; Kanter, CT; Smolders, EJ; van Crevel, R | 1 |
| Bhore, R; Box, T; Gitlin, N; Kowdley, KV; Lalezari, JP; Nelson, DR; Noviello, S; Poleynard, G; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Siddique, A | 1 |
| Cohen, AF; Hessel, MH; Rissmann, R | 1 |
| Al Zoairy, R; Beinhardt, S; Ferenci, P; Freissmuth, C; Hofer, H; Kozbial, K; Maieron, A; Schmidt, A; Stättermayer, AF; Stauber, R; Stern, R; Strasser, M; Trauner, M; Watschinger, B; Zoller, H | 1 |
| Chang, SY; Cheng, Y; Humphreys, WG; Li, W; Ma, L | 1 |
| Basalious, EB; Bendas, ER; Karim, IA; Rezk, MR | 1 |
| Abe, H; Atsukawa, M; Eguchi, Y; Fujiwara, K; Hasegawa, I; Hirashima, N; Iio, E; Kang, JH; Kuramitsu, T; Kusakabe, A; Matsui, T; Miyaki, T; Nojiri, S; Nomura, H; Shimada, N; Shinkai, N; Takaguchi, K; Tanaka, Y; Tsubota, A; Yoshizawa, K | 1 |
| Gschwantler, M; Haltmayer, H; Marchart, K; Moser, S; Schìtz, A | 1 |
| Neumaier, J | 1 |
| Hussar, DA | 1 |
| Faria, R; Griffin, S; Llewellyn, A; Lomas, J; Simmonds, M; Woods, B; Woolacott, N | 1 |
| Arai, M; Haga, Y; Imazeki, F; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Suzuki, E; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Hernandez, D; Huang, X; Kirov, S; McPhee, F; Pant, S; Yu, F | 1 |
| Ampuero, J; Reddy, KR; Romero-Gomez, M | 1 |
| Tanaka, Y | 1 |
| Casanovas, T; Niubó, J; Roca, J | 1 |
| Burger, D; Gevers, TJ; Kooistra, MP; Richter, C; Schipper-Reintjes, E | 1 |
| Assy, N; Dong, Y; Flisiak, R; Gadano, A; Kao, JH; Kawazoe, S; Kumada, H; Lee, KS; Portsmouth, S; Srinivasan, S; Xu, D; Znoyko, O; Zwirtes, R | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Nishimura, D | 1 |
| Hattori, N; Hiraishi, T; Ikeda, H; Ishii, T; Itoh, F; Izumi, N; Kobayashi, M; Kurosaki, M; Matsumoto, N; Matsunaga, K; Nakano, H; Okuse, C; Shigefuku, R; Suzuki, M; Watanabe, T; Yamada, N; Yamamoto, H; Yasuda, H; Yasuda, K; Yotsuyanagi, H | 1 |
| Bogomolov, P; Cooney, E; Critelli, L; Olveira, A; Pol, S; Reesink, HW; Santagostino, E; Srinivasan, S; van Erpecum, K; Xu, D | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A | 1 |
| Lee, HL; Nam, HC; Song, MJ; Yang, H | 1 |
| Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R | 1 |
| Aichelburg, MC; Bucsics, T; Chromy, D; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Asahina, Y; Asano, Y; Azuma, S; Goto, F; Itsui, Y; Kakinuma, S; Kaneko, S; Kawai-Kitahata, F; Miyoshi, M; Murakawa, M; Nagata, H; Nakagawa, M; Nishimura-Sakurai, Y; Nitta, S; Otani, S; Tohda, S; Tojo, N; Tsunoda, T; Watanabe, M | 1 |
| Arya, N; Buchanan, AM; Choukour, M; Eley, T; Huang, SP; Ross, LL; Song, IH; Wynne, B; Zong, J | 1 |
| Desnoyer, A; Lê, MP; Peytavin, G; Yazdanpanah, Y | 1 |
| Chtioui, H; Decosterd, LA; Moradpour, D; Pascual, M; Saouli, AC; Stucker, F; Vionnet, J | 1 |
| Bailly, F; Choupeaux, L; Gagnieu, MC; Maynard, M; Pradat, P; Scholtès, C; Virlogeux, V; Zoulim, F | 1 |
| Chayama, K; Fujiyama, S; Hu, W; Ido, A; Ikeda, F; Inada, Y; Ishikawa, H; Karino, Y; Kumada, H; Linaberry, M; McPhee, F; Naganuma, A; Suzuki, F; Swenson, ES; Takaguchi, K; Tanaka, K; Tomita, E; Toyota, J; Watanabe, H; Yin, PD; Yoshiji, H | 1 |
| Box, TD; Brasher, BB; Buggisch, P; Cao, H; Colvin, R; Jiang, L; Lawitz, E; Lin, K; McAllister, N; Or, YS; Owens, CM; Peng, X; Polemeropoulos, A; Poordad, F; Qiu, YL; Rhodin, MH; Rondon, J; Wang, C; Ying, L; Zeuzem, S | 1 |
| Aikata, H; Chayama, K; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Ochi, H; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S | 1 |
| Burger, DM; D'avolio, A; de Kanter, CT; Di Perri, G; Smolders, EJ; van 't Veer, N; van Wijngaarden, P | 1 |
| Chayama, K; Hayes, CN | 1 |
| Keating, GM | 1 |
| Christensen, S; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL | 1 |
| Chen, YP; Pi, SN | 1 |
| Berg, T; Ferenci, P; Gschwantler, M; Herzer, K; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, J; Spengler, U; van der Valk, M; Wedemeyer, H; Weiland, O; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| DeGray, B; Han, Z; Hartman-Neumann, S; Hernandez, D; McPhee, F; Ueland, J; Vellucci, V; Zhou, N | 1 |
| Alric, L; Billaud, E; Bourcier, V; Bourliere, M; Bronowicki, JP; Carrat, F; Causse, X; Chazouilleres, O; D'Alteroche, L; Diallo, A; Dorival, C; Fontaine, H; Fouchard-Hubert, I; Geist, C; Gournay, J; Guyader, D; Habersetzer, F; Hezode, C; Larrey, D; Ledinghen, VD; Loustaud-Ratti, V; Lucier, S; Marcellin, P; Mathurin, P; Metivier, S; Minello, A; Petrov-Sanchez, V; Pol, S; Riachi, G; Rosa, I; Saillard, E; Samuel, D; Thabut, D; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Kimura, Y; Kobayashi, T; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Nelson Hayes, C; Ochi, H; Takahashi, S; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S | 1 |
| Damrah, I; Eurich, D; Gül-Klein, S; Pratschke, J; Raschzok, N; Reutzel-Selke, A; Sauer, IM; Schott, E; Stockmann, M; Strücker, B | 1 |
| Gao, M; O'Boyle, DR; Roberts, S | 1 |
| Abe, H; Aikata, H; Chayama, K; Chowdhury, S; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Makokha, GN; Miki, D; Ochi, H; Tateno, C; Tsuge, M; Uchida, T | 1 |
| Bertz, R; Bifano, M; Eley, T; Garimella, T; Huang, SP; Kandoussi, H; Wang, R; You, X | 1 |
| De Weggheleire, A; Dorlo, TP; Francque, S; Lynen, L; Meessen, B; Newton, PN; Pouget, C; Ravinetto, R; Sokkab, A; Tabernero, P | 1 |
| Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Arias, A; Baños, I; Benítez-Gutiérrez, L; Citores, MJ; Cuervas-Mons, V; de Mendoza, C; Duca, A; Requena, S; Treviño, A | 1 |
| Beck, KR; Khalili, M; Kim, N | 1 |
| Liu, P; Wang, Y | 1 |
| Hirashima, N; Ikeda, H; Imamura, J; Itoh, F; Iwase, H; Matsumoto, N; Okuse, C; Ryuge, N; Shimada, M; Tanaka, Y; Watanabe, T; Yokomaku, Y | 1 |
| Amemiya, M; Koshima, Y; Kuriyama, S; Maruyama, Y; Morisawa, N; Satoh, JI; Yokoo, T | 1 |
| Abe, T; Asahina, Y; Enomoto, N; Hasebe, C; Hisai, H; Ide, Y; Itakura, J; Izumi, N; Joko, K; Kobashi, H; Kurosaki, M; Mitsuda, A; Murakawa, M; Ogawa, C; Okushin, H; Osaki, Y; Sakita, S; Satou, T; Takaguchi, K; Tamada, T; Tsuji, K; Tsuruta, S; Yagisawa, H | 1 |
| Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Kasai, H; Moriishi, K; Otoguro, T; Tanaka, T; Yamashita, A | 1 |
| Burger, DM; Colbers, EP; de Kanter, CT; Drenth, JP; Smolders, EJ; Velthoven-Graafland, K | 1 |
| Cao, Y; Huo, N; Lu, H; Wu, C; Xu, X; Zhang, R; Zhang, X; Zhang, Y | 1 |
| Botta-Fridlund, D; Hachicha, M | 1 |
| Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S | 1 |
| Ingiliz, P; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, JK; Van der Valk, M; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Boglione, L; Carcieri, C; Cardellino, CS; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
| Beets, G; Beumont, M; Gutierrez, JA; Jacquemyn, B; Kakuda, TN; Lawitz, E; Luo, D; Ouwerkerk-Mahadevan, S; Picchio, G; Poordad, F; Van Eygen, V; Van Remoortere, P; Vandevoorde, A; Vijgen, L | 1 |
| Hiraoka, A; Ishikawa, T; Kumada, T; Okanoue, T; Senoh, T; Shima, T; Shimada, N; Tachi, Y; Tada, T; Takaguchi, K; Toyoda, H; Tsuji, K | 1 |
| Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V | 1 |
| Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S | 1 |
| Boson, B; Chamot, C; Cosset, FL; Denolly, S; Dreux, M; Turlure, F | 1 |
| Ahmed, M; Barakat, K; Houghton, M; Pal, A | 1 |
| Chayama, K; Hayes, CN; Imamura, M | 1 |
| Basso, M; Celegato, M; Loregian, A; Messa, L; Nannetti, G; Pagni, S; Palù, G; Parisi, SG | 1 |
| Flamm, S; Hughes, EA; Kayali, Z; Kwo, P; Lawitz, EJ; Linaberry, M; McPhee, F; Sulkowski, MS; Swenson, ES; Torbeyns, A; Yin, PD | 1 |
| Alberti, A; Bonfanti, M; Croce, D; Lazzarin, A; Nappi, C; Restelli, U | 1 |
| Hernandez, D; McPhee, F; Zhou, N | 1 |
| Berg, T; Ferenci, P; Herzer, K; Hinrichsen, H; Inderson, A; Jimenez-Exposito, MJ; Klinker, H; Peck-Radosavljevic, M; Spengler, U; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kumada, T; Kuzuya, T; Nakano, I; Urano, F; Yoshioka, K | 3 |
| Gan, T; Lu, J; Tao, W; Zhong, J | 1 |
| Chen, PJ; Hong, CM; Liu, CJ; Yeh, SH | 1 |
| Fujisaka, Y; Inoue, J; Kakazu, E; Kanno, A; Kobayashi, T; Kogure, T; Miura, M; Morosawa, T; Nakamura, T; Ninomiya, M; Shimosegawa, T; Takai, S; Umetsu, T; Wakui, Y | 1 |
| Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J | 1 |
| Bucher, HC; Calleja, JL; Castells, L; Evans, D; Giostra, E; Hofer, H; Irving, W; Lefevre, C; Pascasio, JM; Postema, R; Prieto, M; Weiland, O; Weis, N; Young, J | 1 |
| Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Imanaka, D; Inada, Y; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Oshige, A; Saishoji, A; Sakae, H; Tabu, K; Tamai, T; Taniyama, O; Uto, H | 1 |
| Huang, J; Liao, H; Tan, P; Yan, X; Zhu, Z | 1 |
| Yu, ML | 1 |
| Hagiwara, H; Hikita, H; Hiramatsu, N; Iio, S; Imai, Y; Kai, Y; Kato, T; Kondo, Y; Morishita, N; Murai, K; Naito, M; Nakabori, T; Nishiuchi, M; Oze, T; Sakamori, R; Suemizu, H; Takehara, T; Tamura, S; Tatsumi, T; Tsutsui, S; Yakushijin, T; Yamada, R | 1 |
| Almasio, PL; Bourgeois, S; Brown, A; Buggisch, P; DeMasi, R; Diago, M; Gaeta, GB; Hézode, C; Horsmans, Y; Lonjon-Domanec, I; Omoruyi, E; Planas, R; Schlag, M; Serfaty, L; Szalay, F; Zeuzem, S | 1 |
| Akremi, R; Bennai, Y; Botta-Fridlund, D; Bourliere, M; Boyer, N; Bronowicki, JP; D'Alteroche, L; De Ledinghen, V; Di Martino, V; Fedchuk, L; Filipovics, A; Fontaine, H; Guyader, D; Hézode, C; Hubert-Fouchard, I; Larrey, D; Lebray, P; Leroy, V; Nguyen-Khac, E; Rosa, I; Silvain, C; Zhao, Y; Zoulim, F | 1 |
| Baker, MM; Belal, TS; El-Kafrawy, DS; Mahrous, MS | 1 |
| Ackerman, P; Berenguer, J; Cheinquer, H; Côté, P; Dieterich, D; Eley, T; Fessel, WJ; Gadano, A; Hernandez, D; Hughes, E; Lazzarin, A; Liu, Z; Matthews, G; McPhee, F; Mendez, P; Molina, JM; Moreno, C; Noviello, S; Pineda, JA; Pulido, F; Rivero, A; Rockstroh, J; Sulkowski, MS; Zakharova, N | 1 |
| Lim, SG | 1 |
| Castedal, M; Cederberg, S; Segenmark, M; Skoglund, C; Weiland, O | 1 |
| Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y | 1 |
| Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B | 1 |
| Alric, L; Bellier, B; Cacoub, P; Comarmond, C; Costopoulos, M; Desbois, AC; Fontaine, H; Garrido, M; Klatzmann, D; Le Garff-Tavernier, M; Maciejewski, A; Musset, L; Pol, S; Poynard, T; Rosenzwajg, M; Saadoun, D; Si Ahmed, SN | 1 |
| Conway, B; Lazzarin, A; Luetkemeyer, A; Molina, JM; Nelson, M; Portsmouth, S; Romanova, S; Rubio, R; Srinivasan, S; Xu, D | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Alric, L; Bouyer, AS; Cacoub, P; Comarmond, C; de Saint Martin, L; Ferfar, Y; Hezode, C; Musset, L; Pol, S; Poynard, T; Resche Rigon, M; Saadoun, D; Si Ahmed, SN | 1 |
| Ganz, ML; Gorsh, B; Hede, S; Moorjaney, D; Saint-Laurent Thibault, C; Sill, B; Yuan, Y | 2 |
| Andreone, P; Berenguer, M; Calleja, JL; Cieciura, T; Donato, MF; Durlik, M; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Jessner, W; Kalmeijer, R; Lenz, O; Mariño, Z; Ouwerkerk-Mahadevan, S; Peeters, M; Shukla, U; Sterneck, M; Verbinnen, T | 1 |
| Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH | 1 |
| Hashinokuchi, S; Kataoka, S; Kumada, T; Mizuno, K; Sone, Y; Tada, T; Toyoda, H | 1 |
| Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y | 1 |
| Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D | 1 |
| Bae, YS; Bartenschlager, R; Jo, E; Kim, HY; Lee, JY; Lee, M; Shin, EC; Windisch, MP; Yang, J | 1 |
| Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R | 1 |
| Alston, S; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Reau, N; Reddy, KR; Reeve, B; Sarkar, S; Sterling, RK; Stewart, P | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK | 1 |
| Endo, T; Murakami, R; Nakamura, M; Nakamura, N; Narita, I; Shimada, M; Tomita, H; Yamabe, H | 1 |
| Inuzuka, T; Marusawa, H; Nasu, A; Osaki, Y; Sekine, A; Seno, H; Takeda, H; Takemura, R; Ueda, Y; Umeda, M; Yamashita, Y | 1 |
| Bregigeon, S; Colson, P; Dhiver, C; Lacarelle, B; Menard, A; Poizot-Martin, I; Ravaux, I; Ressiot, E; Ruiz, JM; Solas, C; Taton, A; Tomei, C | 1 |
| Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Ahn, SH; Chang, TT; Chu, CJ; Heo, J; Hu, TH; Hu, W; Isakov, V; Kao, JH; Lee, YJ; Lim, YS; McPhee, F; Paik, SW; Peng, CY; Scott Swenson, E; Treitel, M; Yin, PD; Yoon, KT; Yu, ML | 1 |
| Deming, P; Martin, MT | 1 |
| Aizawa, Y; Endo, D; Hokari, A; Satoh, K; Shimada, N | 1 |
| Akriviadis, E; Arvaniti, P; Bellou, A; Dalekos, GN; Goulis, I; Karatapanis, S; Kattamis, A; Koskinas, J; Kountouras, D; Kourakli, A; Maragkos, K; Papatheodoridis, GV; Petropoulou, F; Sinakos, E; Tampaki, M; Toli, B; Triantos, C; Tsiaoussis, G; Vassiliadis, T; Vlachaki, E; Zachou, K | 1 |
| Goto, H; Hattori, M; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kawashima, H; Kuzuya, T; Tachi, Y | 1 |
| Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S; Yoshida, K | 1 |
| Aarnoutse, RE; Burger, DM; Colbers, A; de Kanter, CTMM; Drenth, JPH; Smolders, EJ; Tack, CJ; van Ewijk-Beneken Kolmer, N; Velthoven-Graafland, K; Wolberink, LT | 1 |
| Fujikawa, T; Iwabuchi, S; Matsui, K; Nagata, M; Nakano, M; Nakazaki, H; Shimizu, H; Takatsuka, K; Tanemura, H; Watanabe, T | 1 |
| Arataki, K; Chayama, K; Furusyo, N; Furuya, K; Hiraoka, A; Iio, E; Ikeda, H; Ishikawa, T; Katamura, Y; Kato, K; Kawakami, Y; Kudo, M; Kumada, T; Kurosaki, M; Mori, N; Morikawa, K; Nagasaka, A; Nakai, M; Ogawa, K; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Suzuki, M; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsuji, K; Ueno, Y; Yamamoto, Y; Yamsaki, S | 1 |
| Harada, S; Iida, T; Koshino, K; Masuda, K; Matsuyama, T; Nakamura, T; Nobori, S; Ushigome, H; Yoshimura, N | 1 |
| Bañares, R; Casafont, F; Castellote, J; Castells, L; Cuervas-Mons, V; Espinosa, MD; Fernández, I; García-Gonzalez, M; González, A; González-Diéguez, L; Herrero, JI; Llaneras, J; Londoño, MC; Lorente, S; Molina Pérez, E; Montero Alvarez, JL; Narváez, I; Otero, A; Pascasio, JM; Pascual, S; Pons, JA; Prieto, M; Salcedo, M; Sánchez-Antolín, G; Sousa, JM; Testillano, M; Vinaixa, C | 1 |
| Chang, CS; Lee, SW; Lee, TY; Lu, IT; Yang, SS; Yeh, HZ | 1 |
| Bielen, R; Bourgeois, S; Brixko, C; Cool, M; Cools, W; D'heygere, F; De Galocsy, C; Decaestecker, J; Janssens, F; Moreno, C; Mulkay, JP; Nevens, F; Robaeys, G; Van Overbeke, L; Van Steenkiste, C; Van Vlierberghe, H; Vanwolleghem, T; Verlinden, W | 1 |
| McEwan, P; Mishina, S; Wang, F; Ward, T; Webster, S; Wygant, G | 1 |
| Angarano, G; Bruno, G; Dell'Acqua, R; Fabrizio, C; Lo Caputo, S; Milano, E; Milella, M; Monno, L; Saracino, A; Scudeller, L | 1 |
| Aggarwal, R; Bhargava, R; Goel, A; Rai, P | 1 |
| Balslev, U; Belard, E; Dalgard, O; Färkkilâ, M; Hallager, S; Heggelund, L; Karlsen, L; Krarup, H; Lagging, M; Lund Laursen, A; Madsen, LG; Noraberg, G; Skalshøi Kjær, M; Thorup Røge, B; Weiland, O; Weis, N; Øvrehus, A | 1 |
| Alhussain, K; Kamal, K; Patel, J; Shah, D; Zhao, X | 1 |
| Bhayani, V; Desai, P; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Patel, S | 1 |
| Britto, K; Cameron, R; Cheung, W; Kemp, W; Roberts, SK | 1 |
| Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M | 1 |
| Ida, Y; Iguchi, M; Kato, J; Kawashima, A; Kitano, M; Maekita, T; Moribata, K; Nakao, T; Shimizu, R; Shingaki, N; Taki, S; Tamai, H | 1 |
| Kim, JK; Lee, JI; Lee, KS; Yu, JH | 1 |
| Barnes, E; Brown, A; de Vree, JML; Klenerman, P; Kootstra, NA; Reesink, HW; Sinnige, MJ; Stelma, F; Swadling, L; van der Ree, MH; van der Valk, M; van Nuenen, AC; Willemse, SB | 1 |
| Kim, HJ; Lee, HW; Won, JW; Yoo, KY | 1 |
| Akamatsu, N; Eguchi, S; Furukawa, H; Goto, R; Honda, M; Ikegami, T; Inomata, Y; Ishiyama, K; Kitagawa, Y; Kokudo, N; Ku, Y; Kuramitsu, K; Maehara, Y; Ohdan, H; Okajima, H; Shimada, M; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yanaga, K; Yoshizumi, T | 1 |
| Ahmed, AM; Doheim, MF; Hirayama, K; Hoa, PTL; Huy, NT; Mattar, OM; Sherif, NA; Truong, DH | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ogasawara, N; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Alves, MP; Banda, D; Behrendt, P; Colpitts, CC; Manns, MP; Menzel, N; Meuleman, P; Perin, P; Pfaender, S; Pietschmann, T; Schang, LM; Steinmann, E; Thiel, V; Vondran, FWR | 1 |
| Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX | 1 |
| Brunetto, MR; Chayama, K; Gadano, A; Gerken, G; Ghesquiere, W; Heo, J; Kumada, H; Lawitz, EJ; Levin, J; Linaberry, M; Liu, Z; McPhee, F; Noviello, S; Peng, CY; Pol, S; Reddy, KR; Silva, M; Strasser, SI; Thuluvath, PJ; Toyota, J; Yang, R | 1 |
| Bassiony, MAA; Hanafy, AS; Hussein, S; Mohamed, MS | 1 |
| Chen, DS; Chen, PJ; Chen, YS; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Wang, SS; Yang, HC | 1 |
| Burchill, MA; Crochet, N; Dran, RJ; Edwards, MG; Gale, M; Kriss, MS; Roby, JA; Rosen, HR; Stone, AE; Wind-Rotolo, M | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Kono, M; Kudo, M; Minami, T; Minami, Y; Nishida, N; Takita, M; Ueshima, K; Yada, N | 1 |
| Aoki, T; Gatanaga, H; Kikuchi, Y; Kinai, E; Mizokami, M; Mizushima, D; Oka, S; Sugiyama, M; Teruya, K; Tsukada, K; Uemura, H; Watanabe, K | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Aburawash, A; Elsisi, GH; Waked, E | 1 |
| Ariaudo, A; Avataneo, V; Boglione, L; Carcieri, C; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Favata, F; Guido, F; Mornese Pinna, S | 1 |
| Wise, J | 1 |
| Amemiya, F; Asahina, Y; Enomoto, N; Fukasawa, M; Inoue, T; Kuratomi, N; Maekawa, S; Matsuda, S; Miura, M; Murakawa, M; Muraoka, M; Nakagawa, M; Nakakuki, N; Nakayama, Y; Sakamoto, M; Sato, M; Sato, T; Suzuki, Y; Takano, S; Tatsumi, A; Yamaguchi, T | 1 |
| Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A | 1 |
| Abdo, AM; El-Khayat, HR; El-Shabrawi, MH; Yakoot, M | 1 |
| Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM | 1 |
| Clark, A; Dusheiko, G; Fathi, H; Hill, NR | 1 |
| Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG | 1 |
| AbdAllah, M; Doss, W; El Akel, W; El Kassas, M; El Shazly, H; El Shazly, Y; Elbaz, T; Elsaeed, K; Esmat, G; Gomaa, AA; Ismail, SA; Korany, M; Nasr, A; Omar, H; Said, M; Shaker, MK; Waked, I; Yousif, M | 1 |
| Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U | 1 |
| Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H | 1 |
| Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A | 1 |
| Chida, T; Ito, J; Kawata, K; Kobayashi, Y; Matsunaga, E; Noritake, H; Ohta, K; Shimoyama, S; Suda, T; Suzuki, T; Yamazaki, S | 1 |
| Canini, L; Chayama, K; Cotler, SJ; Dahari, H; Imamura, M; Kawakami, Y; Uprichard, SL | 1 |
| Hidaka, H; Inoue, T; Koizumi, W; Kubota, K; Murakami, S; Nakatani, S; Nakazawa, T; Shibuya, A; Takeuchi, A; Tanaka, Y; Uojima, H; Yamane, K | 1 |
| Buti, M; Chen, Q; Esteban, JI; Esteban, R; Garcia-Cehic, D; Gregori, J; Llorens, M; Nieto-Aponte, L; Ordeig, L; Perales, C; Quer, J; Riveiro-Barciela, M; Rodriguez-Frias, F; Soria, ME | 1 |
| Chen, TY; Dong, J; Gao, H; He, YL; Hu, CH; Liu, JF; Ren, DF; Yan, TT; Yang, SJ; Yang, Y; Zhao, YR; Zhu, L | 1 |
| Espinoza, MA; Giglio, A; Soza, A; Vargas, C | 1 |
| AbuTarif, M; Bhatnagar, R; Chang, YT; Eley, T; Garimella, T; LaCreta, F; Myers, E; Rana, J; Sims, K; Tao, X; Wind-Rotolo, M | 1 |
| Chevaliez, S; Fourati, S; Francois, M; Guedj, J; Hézode, C; Mallat, A; Nguyen, THT; Pawlotsky, JM; Poiteau, L; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Asselah, T; Bellissant, E; Bourlière, M; Bronowicki, JP; Canva, V; Diallo, A; Fontaine, H; Laforest, C; Leroy, V; Loustaud-Ratti, V; Ouzan, D; Petrov-Sanchez, V; Renault, A; Roulot, D; Rousseau, C; Schischmanoff, O; Serfaty, L; Thibault, V; Zoulim, F | 1 |
| Dore, GJ; Grebely, J; Hajarizadeh, B; Martinello, M; Matthews, GV | 1 |
| Beumont, M; Corregidor, AM; Feld, JJ; Felizarta, F; Gamil, M; Ghalib, R; Kakuda, TN; Khalid, O; Lawitz, E; Luo, D; Ouwerkerk-Mahadevan, S; Smith, WB; Sulkowski, MS; Van Eygen, V; Van Remoortere, P; Vijgen, L | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Fabbri, G; Libertone, R; Notari, S; Tempestilli, M | 1 |
| Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI | 1 |
| Elhenawee, M; Hashem, H; Ibrahim, AE; Saleh, H | 1 |
| Baek, K; Beldar, S; Cho, NJ; Grüber, G; Manimekalai, MSS; Yoon, HS | 1 |
| El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Mehrotra, M; Rai, P; Sharma, RK; Verma, P | 1 |
| Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C | 1 |
| Bertz, RJ; Eley, T; Fura, A; Gandhi, Y; Garimella, T; Li, W | 1 |
| Abd El Latif, Y; Alboraie, M; Doss, W; El Kassas, M; El Tahan, A; El-Serafy, M; Elakel, W; Elsaeed, K; ElShazly, Y; Esmat, G; Ezzat, S; Korany, M; Nabeel, MM; Omran, D | 1 |
| Asatryan, A; Asselah, T; Bourlière, M; Bruck, R; Chuang, WL; Dore, GJ; Feld, JJ; Felizarta, F; Flamm, S; Flisiak, R; Foster, GR; Fu, B; Fuster, F; Gane, E; Kaita, K; Kort, J; Kwo, P; Lin, CW; Liu, R; Mensa, FJ; Ng, TI; Paik, SW; Pilot-Matias, T; Pol, S; Poordad, F; Puoti, M; Roberts, SK; Ruane, PJ; Sepulveda-Arzola, G; Soto-Malave, R; Stedman, CA; Tam, E; Trinh, R; Vargas, HE; Vierling, J; Wang, S; Wedemeyer, H; Zeuzem, S | 1 |
| Asahina, A; Chihara, M; Kikuchi, S; Nakagawa, H; Umezawa, Y | 1 |
| Ahn, SH; Han, KH; Jeong, Y; Kim, BK; Kim, DY; Kim, S; Kim, SU; Lee, HW; Oh, SR; Park, JY | 1 |
| Lin, H; Liu, Y; Tobe, RG; Wang, Z; Wu, B | 1 |
| Ansari, MA; Barnes, E; Bonsall, D; Bowden, R; Brown, A; Ip, CLC; Magri, A; Nguyen, D; Piazza, P; Simmonds, P; Smith, D; Trebes, A | 1 |
| Fan, R; Hou, J; Liang, X; Sun, J | 1 |
| Chawla, Y; De, A; Dhiman, RK; Duseja, A; Gupta, KL; Kohli, HS; Kumar, V; Mehta, M; Ramachandran, R; Taneja, S | 1 |
| Akuta, N; Chayama, K; Fujiyama, S; Ido, A; Ikeda, F; Inada, Y; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Naganuma, A; Noviello, S; Takaguchi, K; Tanaka, K; Tomita, E; Toyota, J; Watanabe, H; Yoshiji, H | 1 |
| Cherepanoff, S; Chia, XX; Danta, M; Furlong, T | 1 |
| Araki, N; Eguchi, Y; Iwane, S; Kawakubo, M; Koga, A; Nakashita, S; Oeda, S; Okada, M; Otsuka, T | 1 |
| Kakizaki, S; Kosone, T; Kusano, M; Sato, K; Suzuki, Y; Takagi, H; Takakusagi, S; Yamazaki, Y | 1 |
| Berthillon, P; Bordes, I; Chemin, I; Crouy, S; Larrat, S; Leroy, V; Maynard, M; Petit, MA; Pradat, P; Scholtès, C; Trépo, C; Virlogeux, V; Zoulim, F | 1 |
| AbdElgawad, MM; Abdo, AM; El-Khayat, HR; El-Shabrawi, MH; Helmy, S; Mahfouz, AA; Yakoot, M | 1 |
| Aoufi-Rabih, S; Fabrizi, F; García-Agudo, R; González-Corvillo, C; Salgueira-Lazo, M | 1 |
| Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI | 1 |
| Chang, F; Duan, CA; Jin, X; Lu, Y | 1 |
| Hu, J; Li, C | 1 |
| Elmasry, MS; Hassan, WS; Shalaby, AA; Zidan, DW | 1 |
| Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML | 1 |
| ElBasiony, M; Hassan, AA; Mikhail, NNH; Shiha, G; Soliman, R | 1 |
| Gupta, E; Kataria, A; Nayak, SL; Sarin, SK | 1 |
| Jung, J; Kirchner, VA; Kwon, JH; Lee, SG; Song, GW; Tak, EY | 1 |
| Furqan, S; Jabeen, S; Rashid, O | 1 |
| Alao, H; Cam, M; Fourie, NH; Ghany, MG; Henderson, WA; Keembiyehetty, C; Li, Q; Liang, TJ; Park, H; Rehermann, B; Serti, E; Suarez, D; Wright, EC; Zhang, F | 1 |
| Di Cesare, A; Lazzeri, L; Pescitelli, L; Prignano, F; Ricceri, F; Tripo, L | 1 |
| Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M | 1 |
| Abbas, B; Asem, N; Elsharkawy, A; Esmat, G; Gomaa, A; Hassany, M; Maged, A; Mehrez, M; Mostafa, Z; Soliman, M | 1 |
| Hou, MC; Huang, YH; Lan, KH; Lan, KL; Lee, WP; Liao, SX | 2 |
| Abdel-Gabaar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI | 1 |
| Ahn, SH; Han, KH; Jeong, Y; Jin, B; Kim, DY; Kim, S; Lee, HW; Park, HJ; Park, JY | 1 |
| Garg, K; Gupta, GK; Maharshi, S; Nijhawan, S; Padhi, S | 1 |
| Cázares-Cortázar, A; Gaytán-Martínez, J; Gómez-Torres, ME; Martínez-Rodríguez, ML; Mata-Marín, JA; Ocaña-Mondragón, A; Ribas-Aparicio, RM; Uribe-Noguez, LA | 1 |
| Elmasry, MS; Elsayed, HM; Hassan, WS; Zidan, DW | 1 |
| Ariaudo, A; Boglione, L; Carcieri, C; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Favata, F; Guido, F; Pinna, SM | 1 |
| Chung, WJ; Hwang, JS; Jang, BK; Jang, SY; Kim, BS; Kwak, SG; Kweon, YO; Lee, CH; Lee, HJ; Oh, JY; Park, JG; Park, SY; Song, JE; Suh, JI; Tak, WY | 1 |
| Lu, J; Xie, Q; Zhou, HJ | 1 |
| Bhatt, S; Dogra, A; Gour, A; Kotwal, P; Magotra, A; Nandi, U; Sharma, A; Singh, G; Wazir, P | 1 |
| Alavian, SM; Sharafi, H | 1 |
| Esposito, I; Marciano, S; Trinks, J | 1 |
| Chen, W; Gordon, J; Tan, MP; Wang, PF; Ward, T; Wygant, GD; Yan, J | 1 |
| Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR | 1 |
| Conway, B; Thiam, A | 1 |
| Abd El Latif, Y; Doss, W; El Kassas, M; El Shazly, Y; El Tahan, A; Elbadry, M; Esmat, G; Farid, AM; Fontanet, A; Funk, AL; Sherief, A; Shimakawa, Y; Vasiliu, A; Youssef, N | 1 |
| Bando, E; Hatanaka, N; Komoto, A; Nakamura, K; Suzuki, F | 1 |
| Bricks, G; Castelo Filho, A; Figueiredo Senise, J; Grandi, G; Pott-Junior, H | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Makokha, GN; Miki, D; Ochi, H; Osawa, M; Saito, Y; Tateno, C; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Chen, L; Li, B; Ma, L; Qing, J; Zhai, PB; Zhang, LQ | 1 |
| Barone, CR; Bonamigo, RR; Boza, JC; Oliveira, FB; Pires, GC; Rossi, SD; Silva, M | 1 |
| Goto, H; Hattori, M; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Katano, Y; Kumada, T; Kuzuya, T; Toyoda, H | 1 |
| Abdel Wahed, WY; Ahmed, EI; Ahmed, TI; Hassan, EA | 1 |
| Al-Deen Abead, M; Baraka, MA; Gomaa, AA; Hussein, AK; Wahsh, EA | 1 |
| Abdallah, OM; Abdel-Megied, AM; Gouda, AS | 1 |
| Elhenawee, M; Saleh, H; Saraya, RE | 1 |
| Brieva, T; Frias, M; Rivero, A; Rivero-Juarez, A | 1 |
| Garimella, T; Imai, Y; Ishikawa, H; Osawa, M; Ueno, T | 2 |
| Bacca, D; Cenderello, G; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Mazzola, M; Minerva, N; Palmieri, V; Piazzola, V; Potenza, D; Santoro, R; Sogari, F; Terreni, N | 1 |
| Abdel-Lateef, MA; Ali, R; Derayea, SM; Omar, MA | 1 |
| Abdellatif, Z; Anwar, I; Bekheet, N; El-Nahaas, SM; Elhossary, W; Elsharkawy, A; Esmat, G; Fouad, R; Khairy, M; Maher, RM | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Mornese Pinna, S | 1 |
| De, A; Kumar, P; Kumari, S; Singh, A; Singh, V | 1 |
| Aly, HH; Fujiwara, K; Kato, T; Masaki, T; Muramatsu, M; Murayama, A; Shiina, M; Wakita, T; Yamada, N | 1 |
| Cho, H; Kim, GW; Kim, S; Kim, SJ; Lee, SH; Lee, W; Moon, JS; Oh, JW; Pak, BY | 1 |
| Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM | 1 |
| Fujioka, SI; Hagihara, H; Hashimoto, N; Ikeda, F; Iwasaki, Y; Kariyama, K; Kawaguchi, M; Kobashi, H; Kubota, J; Miyatake, H; Mori, C; Morimoto, Y; Moriya, A; Okada, H; Sakaguchi, K; Takaguchi, K; Takaki, A; Takayama, H; Takeuchi, Y; Wada, N; Yasunaka, T | 1 |
| Jagadabi, V; Mahesh, K; Nagaraju, D; Nagendra Kumar, PV; Pamidi, S; Ramaprasad, LA | 1 |
| Fukuhara, T; Furusho, N; Harada, N; Ikegami, T; Itoh, S; Kato, M; Maehara, Y; Shimoda, S; Soejima, Y; Yoshizumi, T | 1 |
| Chen, P; Liu, Q; Ma, A | 1 |
| Bartlett, C; Curd, A; Harris, M; Peckham, M | 1 |
| Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Satsangi, S; Taneja, S | 1 |
| Abdelsameea, E; Essa, M; Sabry, A; Salama, M; Tharwa, ES | 1 |
| Abd Elfatah, AS; Abdalla, NH; Abdel-Raheim, S; Abdulghany, HM; Khairy, RM; Zenhom, NM | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Chen, EQ; Deng, R; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YH; Yuan, M | 1 |
| Imai, Y; Inao, M; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Uchida, Y | 1 |
| Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC | 1 |
| Biggs, BA; Kanhutu, K; Sasadeusz, J; Schulz, TR; Watkinson, S | 1 |
| Eibl, MM; Müller, CJ; Wolf, HM | 1 |
| Ghosh, R; Lahiri, G; Paul, R; Roy, D; Ruia, AV; Sarkar, R; Sau, TJ | 1 |
| Aboshabana, R; Eid, M; El-Enany, N; Shalan, S | 1 |
| Cicchetti, A; De Solda, F; Drago, C; Kondili, LA; Nappi, C; Rolli, FR; Ruggeri, M | 1 |
| Giorgi, C; Hoffmann, HH; Kuchay, S; Li, J; Pagano, M; Pinton, P; Rice, CM; Saeed, M | 1 |
| Chen, J; Deng, H; Huang, H; Shen, J; Tang, H; Wu, J; Xie, W; Zhou, Q | 1 |
| Abdel Gawad, M; Abdel Ghaffar, A; Abdel Ghaffar, TY; El Naghi, S; Helmy, S; Moafy, M; Yousef, M | 1 |
| Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB | 1 |
| Ghesquiere, W; Huhn, GD; Linaberry, M; McPhee, F; Noviello, S; Poordad, F; Ramji, A; Shafran, SD; Shiffman, ML; Wong, A; Wong, F; Yang, R | 1 |
| Chen, EQ; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wu, DB; Zhang, DM | 1 |
| De Maria, C; Ghidotti, I; Giannini, EG; Grillo, F | 1 |
| Jang, JW; Kim, HS; Kim, JH; Kim, SB; Kim, SH; Ko, SY; Kwon, JH; Lee, BS; Lee, SH; Lee, TH; Song, DS; Song, MJ | 1 |
| Jung, BH; Lee, SG; Park, JI | 1 |
| Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA | 1 |
| Algharably, E; Budde, K; Duerr, M; Glander, P; Halleck, F; Hoffmann, F; Jaeger, C; Kreutz, R; Lisec, J; Schrezenmeier, E; Schrezenmeier, J | 1 |
| Khan, AJ; Mohindra, S; Negi, TS; Parmar, D; Ranjan, P; Saraswat, VA | 1 |
| Enomoto, M; Hai, H; Kawada, N; Kumada, H; Okada, M; Tamori, A; Uchida-Kobayashi, S | 1 |
| Borba, HHL; Ferreira, VL; Pontarolo, R; Siqueira, FM | 1 |
| Abou El-Alamin, MM; Azab, MM; Sultan, MA; Wark, AW | 1 |
| Yi, Z; Yuan, Z; Zhang, Y; Zhao, X; Zou, J | 1 |
| Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML | 1 |
| Chen, X; Deng, H; Hu, C; Huang, H; Li, W; Li, Y; Liu, J; Peng, Y; Ren, Y; Wu, T; Yuan, G; Zhang, YY; Zhou, Y | 1 |
| Aboufarrag, GA; Lashen, SA; Madkour, MA; Shamseya, MM | 1 |
| Garimella, T; Li, H; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Baba, M; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Bakr, MA; El Maghrabi, HM; Elmowafy, AY; Elwasif, SM; Zahab, MA | 1 |
| Garimella, T; Ishikawa, H; Li, H; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SHH; Sulaiman, AS; Zulkifly, S | 1 |
| Garimella, T; Green, M; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
| Asahina, Y; Doi, A; Hikita, H; Kai, Y; Kato, T; Kodama, T; Murayama, A; Nakabori, T; Nitta, S; Saito, Y; Sakamori, R; Suemizu, H; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R | 1 |
| Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Ismail, WA; Yousef, AE | 1 |
| Chawla, S; Jain, A; Kalra, BS; Srivastava, S | 1 |
| Clément, V; Raimond, V | 1 |
| Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
| Basha, MAA; Bassiony, MA; Hanafy, AS | 1 |
| Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I | 1 |
| Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R | 1 |
| Chayama, K; Hiraoka, A; Imamura, M; Joko, K; Kudo, M; Kumada, H; Kumada, T; Michitaka, K; Nagano, T; Nakamuta, M; Ogawa, C; Okubo, H; Senoh, T; Shibata, H; Suzuki, Y; Tachi, Y; Tada, T; Takaguchi, K; Takaki, S; Toyoda, H; Tsuji, K; Tsutsui, A; Watanabe, T | 1 |
| Farias, MR; Foppa, AA; Gomes, LO; Rosa, JAD; Rover, MRM; Teixeira, MR | 1 |
| Baker, MM; Belal, TS; Hammad, SF | 1 |
| Babudieri, S; Barbarini, G; Candilo, FD; Cariti, G; Dell'Isola, S; Distefano, M; Ettorre, GM; Fontanella, L; Giannelli, V; Iovinella, V; Ippolito, AM; Izzi, A; Marignani, M; Messina, V; Moretti, A; Palitti, VP; Pellicelli, A; Pompili, M; Scifo, G; Tarquini, P; Vennarecci, G; Vignally, P | 1 |
| Abdul-Rahman, E; Ali, R; Elsutohy, MM; Khorshed, A; Oraby, M | 1 |
| Bagaglio, S; Ferrari, D; Galli, L; Hasson, H; Locatelli, M; Messina, E; Morsica, G; Premaschi, S; Raso, M; Uberti-Foppa, C | 1 |
| El-Kosasy, AM; Hussein, LA; Magdy, N; Youssef, AA | 1 |
| Brandão-Mello, CE; Costa, VD; de Souza Rodrigues, LLLX; do Amaral Mello, FC; Dos Santos Silva, PGC; Lampe, E; Nunes, EP | 1 |
| Chen, JH; Dong, B; Jiang, JD; Li, H; Li, JR; Liu, NN; Lv, XQ; Peng, ZG; Tan, JL; Zou, LL | 1 |
| Bwa, AH; Hlaing, NKT; Kyaw, AMM; Lin, S; Loza, BL; Maung, MZ; Maung, ST; Myint, KT; Nangia, G; Reddy, KR; Sein Win, S; Tun, KT; Win, KM | 1 |
| Bermúdez, C; Cheinquer, H; Coelho Borges, S; de Araujo, A; de Maman, Í; Fleck, A; Gadano, A; Garrastazul, P; Haddad, L; Kliemann, D; Marciano, S; Mendizabal, M; Nader, LA; Piñero, F; Ridruejo, E; Silva, M; Wolff, FH | 1 |
| Huang, Y; Marshall, J; Miller, SA; Su, BN | 1 |
| Allam, AS; Hussein, HA; Moaty, ASA | 1 |
| Abdelrazik, M; Aboushady, M; Alwassief, A; Elbahrawy, A; Elmestikawy, A; Shahba, H; Ziada, D | 1 |
| DeMichele, M; Gu, H; Pillutla, R; Zeng, J; Zhang, YJ; Zhao, Y; Zheng, N | 1 |
| AbdElgawad, MM; Abdo, AM; El-Khayat, HR; El-Shabrawi, MH; Helmy, S; Kamal, EM; Kamal, NM; Khalil, AF; Mahfouz, AA; Yakoot, M | 1 |
| Wahid, B | 2 |
| Aleem, A; Khan, AA; Sarwar, S; Tarique, S | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Wu, SH | 1 |
| Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ | 1 |
| Abe, H; Agata, R; Atsukawa, M; Itokawa, N; Kato, K; Matsumoto, Y; Shimada, N; Tsubota, A | 1 |
| Alavi, M; Dore, GJ; Grebely, J; Hajarizadeh, B; Kaveh-Ei, S; Malekzadeh, R; Merat, S; Poustchi, H; Rahimi-Movaghar, A; Shadloo, B | 1 |
| Abdel-Reheem, AY; Basalious, EB; Boseila, AA | 1 |
| Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Wang, YJ; Wu, SH | 1 |
| Gao, XH; Jing, P | 1 |
| Gaballah, AH; Ghazy, AA; Mostafa, H; Osman, EM; Rashwan, EA; Tawfik, S | 1 |
| Chen, KY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Ko, YM; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM | 1 |
| Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP | 1 |
| Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ | 1 |
| Cecka, F; Cerveny, L; Huliciak, M; Martinec, O; Staud, F; Vokral, I | 1 |
| Merat, S | 1 |
| Abdel-Reheem, AY; Basalious, EB; Boseila, AA; Rashed, HM; Sakr, TM | 1 |
| Aguiar, BF; Bittar, C; Campos, GRF; Marques, NN; Martinelli, ALC; Molina, BF; Pereira, LRL; Rahal, P; Rodrigues, JPV; Souza, FF | 1 |
| Anis, AH; Azim, T; Chowdhury, EI; Faruque, MO; Janjua, NZ; Kabir, A; Khan, SI; Rahman, M; Reza, M; Sarker, MS; Shafiq, TKI | 1 |
| Abdelaty, LN; Elnaggar, AA; Hussein, RRS; Said, AA | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
| El Atrache, LL; Labidi, A | 1 |
| Ariyoshi, N; Chiba, N; Fujiyoshi, M; Kato, Y; Kawauchi, A; Matsumoto, J; Nakamura, H; Sakaue, H; San, SN; Sanbe, R; Tagai, R; Yamada, H; Yanaka, S | 1 |
| Kim, JW | 1 |
| Desai, A; Gorad, S; Jagdale, A; Kasbale, A; Kulkarni, A; Samanta, G; Tawde, H; Tol, T | 1 |
| Costa, VD; Lago, BV; Lampe, E; Mello, FCA; Nunes, EP; Pellegrini, P; Pittella, AM; Rotman, V | 1 |
| Calil-Elias, S; Crisante, VC; Cursino, CN; de Almeida, RMVR; Duarte, GDS; Giordani, F; Monteiro, PGO; Vieira, TBQ; Xavier, AR | 1 |
| Abd El-Wahab, EW; Helmy, SH; Nagaty, A | 1 |
| Cheema, SS; Cheema, SUR; Gilani, N; Hussain, G; Rehman, MS | 1 |
| Abdelkawy, KS; Ebaid, NF; El-Haggar, SM; El-Magd, MA; Elbarbry, FA; Ziada, DH | 1 |
| Buonomo, AR; Gentile, I; Maraolo, AE; Pinchera, B; Scotto, R; Zappulo, E | 1 |
| Abdel Alem, S; Abdel Aziz, H; Abdellatif, Z; Al Askalany, M; Cordie, A; El Akel, W; Elsharkawy, A; Esmat, G; Kamal, W; Kamel, S; Kandeel, A; Meshaal, S | 1 |
| El-Sisi, AE; Zakaria, S | 1 |
| Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C | 1 |
| Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH | 1 |
| Abdel Moneim, A; Mabrouk, D; Mahmoud, B; Suleiman, HA; Zaky, MY | 1 |
| Abbasy, M; Abdu Allah, AM; Elimam, H; Elnaidany, N; Essa, A; Mohamed Ibraheem, KI; Nada, A; Sabry, A; Shehab-Eldeen, S | 1 |
| Huang, CF; Yu, ML | 1 |
| Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG | 1 |
| Bunchorntavakul, C; Charatcharoenwitthaya, P; Chonprasertsuk, S; Komolmit, P; Piratvisuth, T; Sanpajit, T; Sethasine, S; Siripipattanamongkol, C; Sobhonslidsuk, A; Sukeepaisarnjaroen, W; Sutthivana, C; Tangkijvanich, P; Tanwandee, T; Wongpaitoon, V | 1 |
| AbdAlla, M; Abdel Gawad, S; Abdel Megid, S; Abdel-Razek, W; Abo Sliman, M; Abou Hashem, K; Ammar, I; Cordie, A; Dabbous, H; Doss, W; El Akel, W; El Nahas, N; El Shazly, Y; El Sobky, A; El Sonbaty, S; El Tabakh, H; El-Sayed, MH; El-Serafy, M; Elsharkawy, A; Elshishiney, G; Emad, E; Esmat, G; Gemeah, H; Ghalab, R; Hashem, A; Hashish, A; Hassany, M; Hefnawy, N; Hemida, AN; Kabil, K; Kamal, E; Khadary, A; Labib, K; Mahmoud, F; Mamoun, S; Marei, T; Mekky, S; Meshref, A; Omar, Y; Othman, A; Ragab, O; Ramadan, E; Rehan, A; Saad, T; Saeed, R; Salah, A; Sharshar, M; Shawky, H; Shawky, M; Shehata, W; Soror, H; Taha, M; Talha, M; Tealaab, A; Waked, I; Zaid, H; Zein, M | 1 |
| Abou-Samra, AB; Butt, AA; Nasir, B; Rasool, S; Rubi, G; Tayyab, GUN | 1 |
| Feng, Z; Gao, H; Huang, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Wang, X; Xu, L; Zhang, L | 1 |
| Abd-Elsalam, SM; Abdulaziz, BA; El Attar, IH; El Kassas, M; Emadeldeen, M; Said, EM | 1 |
| Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M | 1 |
| Bajis, S; Dore, GJ; Martinello, M | 1 |
| Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR | 1 |
| Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M | 1 |
| Bronowicki, JP; Carrat, F; Chazouillères, O; Chevaliez, S; de Lédinghen, V; Dorival, C; Fontaine, H; Larrey, D; Lusivika-Nzinga, C; Marcellin, P; Metivier, S; Pawlotsky, JM; Pol, S; Samuel, D; Tran, A; Zoulim, F | 1 |
| Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N | 1 |
| Barnes, E; Magri, A; Nguyen, D; Simmonds, P; Smith, D; Vaughan-Jackson, A | 1 |
| Barclay, ST; de Bruin, M; Dillon, JF; Donnan, PT; Fraser, A; Hapca, A; Inglis, SK; Radley, A | 1 |
| Batista, AD; da Silva Sacerdote, AB; de Barros Barreto, S; Filgueira, NA; Lopes, EP | 1 |
| Doi, Y; Hagiwara, H; Hikita, H; Iio, S; Imai, Y; Kai, Y; Kodama, T; Morishita, N; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Urabe, A; Yamada, R; Yamada, T | 1 |
| Alhusseini, MM; Mohamed, GA; Salama, MM; Saleh, SA | 1 |
| Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO | 1 |
| Benute, GRG; CapitÃo, CG; Diament, D; Gascon, MRP; Lucia, MCS; Macedo, EC; Marcusso, RMN; Penalva-DE-Oliveira, AC; Smid, J; Vidal, JE | 1 |
| Bertrand, D; Bouvier, N; Büchler, M; Caillard, S; Chevallier, E; Colosio, C; Garrouste, C; Gatault, P; Le Meur, Y; Rerolle, JP; Rivalan, J; Rostaing, L; Sayegh, J; Thierry, A | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lai, WT; Lee, HC; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Devi, S | 1 |
| Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Imanaka, D; Inada, Y; Kanmura, S; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Saisyoji, A; Sakae, H; Sakurai, K; Tabu, K; Tamai, T; Taniyama, O; Toyodome, A; Uto, H | 1 |
| Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A | 1 |
| Abbaspour Kasgari, H; Alikhani, A; Babamahmoodi, F; Davoudi Badabi, AR; Davoudi, L; Garratt, A; Hedayatizadeh Omran, A; Hill, A; Levi, J; Merat, S; Moradi, S; Saeedi, M; Shabani, AM; Simmons, B; Tirgar Fakheri, H; Wentzel, H | 1 |
| Afhami, S; Akbarpour, E; Ali Asgari, A; Aliannejad, R; Anushirvani, A; Davarpanah, AH; Garratt, A; Hill, A; Hosamirudsai, H; Kheiri, Z; Levi, J; Merat, S; Montazeri, M; Norouzi, A; Qavi, A; Radmard, AR; Sadeghi, A; Simmons, B; Wentzel, H | 1 |
| Bitaraf, S; Eslami, G; Esmaeilian, H; Freeman, J; Hajizadeh Farsani, M; Hill, A; Jafari Kashi, AH; Jelvay, S; Lotfi, Z; Marjani, S; Mobarak, M; Mobarak, S; Momtazan, M; Mousaviasl, S; Radmanesh, E; Sadeghi, A; Salmanzadeh, S; Simmons, B; Tabibi, R; Talebzadeh, SM; Wentzel, H; Wickramatillake, A | 1 |
| Chankvetadze, B; Krait, S; Naumann, L; Neusüß, C; Salgado, A; Scriba, GKE; Villani, C | 1 |
| Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kobara, H; Masaki, T; Mimura, S; Morishita, A; Nakahara, M; Nomura, T; Oryu, M; Oura, K; Sakamoto, T; Shimotohno, K; Tadokoro, T; Takuma, K; Tani, J; Tsutsui, K; Wakita, T; Yoneyama, H | 1 |
| Chalasani, N; Chayama, K; Dulcey, AE; Frankowski, KJ; Hu, X; Hu, Z; Imamura, M; Irvin, PH; Le, D; Li, K; Liang, TJ; Ma, CD; Marugan, JJ; Osawa, M; Park, SB; Rolt, A; Southall, N; Talley, DC; Teraoka, Y; Uchida, T; Wang, AQ; Xu, X | 1 |
| Burger, DM; Colbers, A; Drenth, JPH; Freriksen, JJM; Greupink, R; Meijerhof, M; Russel, FGM; van Drongelen, J | 1 |
| Anees, M; Doss, W; El Akel, W; Eletreby, R; Esmat, G; Hashem, A; Hassany, M; Helmy, A; Khalaf, N; Kobtan, A; Mansour, S; Naguib, M | 1 |
| Abbaspour Kasgari, H; Ali Asgari, A; Eslami, G; Hill, A; Merat, S; Mobarak, S; Sadeghi, A; Simmons, B; Tirgar Fakheri, H; Wentzel, H | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Rai, P; Rungta, S; Tiwari, P; Verma, A | 1 |
| Chen, EQ; Chen, XB; Jiang, W; Li, J; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Xiao, GB | 1 |
| Bittar, C; Chen, S; Fernandes Campos, GR; Harris, M; Martinelli, ALC; Pereira, LRL; Rahal, P; Souza, FF; Vilela Rodrigues, JP; Ward, J | 1 |
| Mendizabal, M; Piñero, F; Ridruejo, E; Silva, M | 1 |
| Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH | 1 |
| Aluzaite, K; Fraser, M; Giles, H; Johnson, S; Schultz, M | 1 |
| Chen, H; Li, C; Liang, J; Tian, J; Xiang, H | 1 |
| Alizadeh-Navaei, R; Hedayatizadeh-Omran, A; Hill, A; Levi, J; Merat, S; Roozbeh, F; Saeedi, M; Shamshirian, A; Wentzel, H | 1 |
| Chan, HT; Chao, CM; Lai, CC | 1 |
| Keyvan, K; Motiee, F; Sohrabi, MR | 1 |
| Callegaro, FS; de Camargo Vieira, MC; Gonçalves, WRB; Guerra, RA; Lazaretti-Castro, M; Maeda, SS | 1 |
| Lee, DH; Lee, SH; Moon, JS; Myung, HJ; Park, TY; Ryu, SH; Shin, YJ | 1 |
| Bilal, M; Farooq, N; Hussain, N; Maqsood, M; Rajoka, MSR | 1 |
| Balkan, S; Bunreth, V; Craig, J; Dousset, JP; Jolivet, P; Le Paih, M; Marquardt, T; O'Keefe, D; Samley, K; Zhang, M | 1 |
| El-Sayed, EM; Hassanien, KS; Helal, GK; Ismail, RS; Zakarya, ZM | 1 |
| Bastos, MM; Boechat, N; Bou-Habib, DC; Bozza, FA; Bozza, PT; Branco, FSC; Chien, M; Da Silva, APD; da Silva, CDS; de Freitas, CS; Dias, SDSG; Fernandes, TVA; Ferreira, AC; Ferreira, MA; Fintelman-Rodrigues, N; Garzia, A; Goto-Silva, L; Guimarães, MZ; Hoelz, LVB; Jockusch, S; Ju, J; Mattos, M; Owen, A; Pão, CRR; Patel, D; Pedrosa, CSG; Rajoli, RKR; Rehen, SK; Russo, JJ; Sacramento, CQ; Saraiva, FB; Soares, VC; Souza, LRQ; Souza, TML; Tao, C; Temerozo, JR; Tuschl, T; Vitória, G; Wang, X; Xie, W | 1 |
| Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K | 1 |
| Abdel-Lateef, MA; Almahri, A | 1 |
| Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C | 1 |
| Kurosaki, K; Uesawa, Y | 1 |
| Abd Elghafar, M; Abd-Elsalam, S; AbdAllah, M; Cordie, A; El-Akel, W; El-Badrawy, A; El-Bendary, M; El-Shazly, M; Elalfy, H; Elbaz, T; Elegezy, M; Elhadidy, T; Esmat, G; Essam, M; Farid, K; Neamatallah, M; Salama, M | 1 |
| Chao, CM; Hsueh, PR; Lai, CC | 1 |
| Afshar Mogaddam, MR; Farajzadeh, MA; Jouyban, A; Khodadadeian, F; Khoubnasabjafari, M | 1 |
| Hasuike, S; Iwakiri, H; Kuroki, K; Kusumoto, K; Matsuura, Y; Mukuda, T; Nagata, K; Nakamura, K; Ochiai, T; Ozono, Y; Shimoda, K; Tsuchimochi, M | 1 |
| Abbassi, M; Al-Nahari, M; Cressey, TR; Easterbrook, P; El-Sayed, MH; Farid, S; Indolfi, G; Lallemant, M; Penazzato, M | 1 |
| Eissa, MS; Fayed, AS; Hegazy, MA; Kamel, EB | 2 |
| Abbass, S; Abdel-Razek, W; Abdelgwad, A; Einar, M; El-Hosieny, E; Elgazzar, M; Elrouby, O; Farouk, M; Helmy, S; Kamal, E; Mahdi, D; Mansour, M; Sabry, A; Saif, M; Sakr, N; Salah, M; Salama, M; Salman, T; Shehab, I; Tharwa, ES; Waked, I | 1 |
| Hwang, SB; Kim, B; Lee, GH; Lee, SG; Lim, YS; Lyoo, KS; Nguyen, LP | 1 |
| El-Nabarawi, M; Elkarmalawy, M; Elmenshawe, S; Nafady, M; Teaima, M | 1 |
| Abbass, A; Abdeen, N; Afify, S; Alboraie, M; El Kassas, M; ELshazly, HM; Eltabbakh, M; Emadeldeen, M; Ezzat, S; Farghaly, R; Ghalwash, A; Hamdy, H; Omar, H; Omran, D; Salaheldin, M; Sweedy, A; Tahoon, M | 1 |
| Ali, A; Anwer, S; Hussain Shah, SS; Kashif, M; Nasiri, MI; S Naqvi, SB; Sarwar, H | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Bellagamba, R; Cicalini, S; Fabbri, G; Grilli, E; Lorenzini, P; Mastrorosa, I; Notari, S; Tempestilli, M; Vergori, A | 1 |
| Abdel-Bary, HM; El Sayed, IET; Ghanm, SE; Othman Saad, W; Saad, BF; Shebl, NA | 1 |
| Tsanni, A | 1 |
| Alsrhani, A; Alzahrani, B; Ejaz, H; Gohar, UF; Junaid, K; Mukhtar, H; Qamar, MU; Younas, S | 1 |
| Abbaspour Kasgari, H; Abdollahi, M; Abedi, F; Afshari, M; Akbarpour, E; Ali Asgari, A; Anushiravani, A; Arizavi, Z; Azarkar, Z; Azimi, E; Babamahmoodi, F; Bahadori, AR; Barahimi, E; Bonyadi, A; Davoodi, L; Davoudi Badabi, AR; Dehghan Manshadi, SA; Dehghani, F; Ebrahimzadeh, A; Ebrahimzadeh, M; Eslami, G; Esmaeilian, H; Fakheri, H; Hasooni Bahrini, N; Hassaniazad, M; Hill, A; Hormati, A; Hosamirudsari, H; Jelvay, S; Joukar, F; Karimi, J; Khajavirad, N; Khodadadi, J; Levi, J; Mansour-Ghanaei, F; McCann, K; Mehrabi, Z; Merat, D; Merat, S; Mirzaei, H; Mobarak, M; Mobarak, S; Moghimi, M; Moslemi, R; Mousavi, H; Mousaviasl, S; Naghipour, M; Nateghi Baygi, A; Nateghi Baygi, H; Nekoukar, Z; Noori Jangi, M; Poormontaseri, Z; Pourmasoomi, H; Radmanesh, E; Rezaie Keikhaie, L; Sadeghi, A; Salasi, M; Salehi, M; Salmanzadeh, S; Sayar, S; Shabani, AM; Shabani, M; Shokouhi, S; Simmons, B; Tousi, A; Wentzel, H; Yaghoubi, S; Yaghubi Kalurazi, T; Yeganeh, S; Zeinali, A; Ziaee, M; Zolfaghari, F | 1 |
| Benkovics, G; Chankvetadze, B; Krait, S; Malanga, M; Salgado, A; Scriba, GKE; Sohajda, T; Szakály, PS | 1 |
| Jang, JY; Jun, DW; Jung, YK; Kim, MY; Kim, SG; Kwon, OS; Lee, JW; Lee, SH; Park, JY; Yoo, HW | 1 |
| Ashmawy, SM; Eltahan, DA; Essa, EA; Osman, MA | 1 |
| Chen, J; Gao, H; Guan, Y; Hua, R; Huang, Y; Jiang, Y; Kong, F; Li, C; Li, G; Ma, H; Mao, X; Meng, C; Niu, J; Tan, Y; Wang, J; Wang, Z; Wen, X; Wu, Q; Xin, Y; Xiong, Q; Xu, B; Zhang, X; Zhang, Y; Zhao, L | 1 |
| El-Demerdash, E; Elbadawy, HA; Wahdan, SA | 1 |
| Chao, CM; Chen, CK; Chen, YH; Kao, JH; Weng, TS | 1 |
| Akpomiemie, G; Bosch, B; Casas, CP; Ellis, L; Hill, A; Johnstone, H; Owen, A; Simmons, B; Sokhela, S; Venter, WDF; Woods, J | 1 |
| Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA | 1 |
73 review(s) available for valine and bms-790052
| Article | Year |
|---|---|
The NS5A replication complex inhibitors: difference makers?
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Discovery; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Discovery; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Treatment Outcome; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Treatment of chronic hepatitis C--are interferons really necessary?
Topics: Antiviral Agents; Carbamates; Cyclophilins; Cyclosporine; Drug Substitution; Hepatitis C, Chronic; Humans; Imidazoles; Immunologic Factors; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Serine Proteinase Inhibitors; Sofosbuvir; Uridine Monophosphate; Valine | 2012 |
Anti-HCV drugs in the pipeline.
Topics: Animals; Antiviral Agents; Carbamates; Cyclosporine; Deoxycytidine; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine; Virus Replication | 2011 |
Hepatitis C viral kinetics: the past, present, and future.
Topics: Antiviral Agents; Carbamates; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Imidazoles; Models, Biological; Oligopeptides; Protease Inhibitors; Pyrrolidines; Silybin; Silymarin; Valine | 2013 |
HCV NS5A inhibitors in development.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
NS5A inhibitors in the treatment of hepatitis C.
Topics: Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2013 |
NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Molecular Structure; Pyrrolidines; Treatment Outcome; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Daclatasvir: potential role in hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2013 |
Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Combinations; Hepacivirus; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
Treatment of hepatitis C virus genotype 3-infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C virus NS5A inhibitors and drug resistance mutations.
Topics: Animals; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mutation; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclosporine; Drug Resistance, Viral; Fluorenes; Hepacivirus; Humans; Imidazoles; Mutation, Missense; Protein Binding; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
Daclatasvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Efficacy of daclatasvir in hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Valine; Viral Nonstructural Proteins | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins | 2015 |
Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Precision Medicine; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine | 2015 |
Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Imidazoles; Practice Guidelines as Topic; Pyrrolidines; RNA-Dependent RNA Polymerase; Valine; Viral Nonstructural Proteins | 2015 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Therapy for hepatitis C genotype 3: moving forward.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Health Care Costs; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2015 |
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2015 |
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
Daclatasvir for the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Discovery; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Molecular Structure; Pyrrolidines; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2015 |
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Male; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
Advances in hepatitis C therapies.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Transplantation; Pyrrolidines; Simeprevir; Sofosbuvir; Valine | 2015 |
Management of direct-acting antiviral agent failures.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine | 2015 |
Asunaprevir for hepatitis C: a safety evaluation.
Topics: Animals; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Protease Inhibitors; Pyrrolidines; Sulfonamides; Valine | 2015 |
Ideal oral combinations to eradicate HCV: The role of ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine | 2016 |
Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Protease Inhibitors; Pyrrolidines; Sulfonamides; Valine | 2015 |
Daclatasvir (Daklinza) for HCV genotype 3 infection.
Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2015 |
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Discovery; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoquinolines; MicroRNAs; Molecular Targeted Therapy; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Nonstructural Proteins | 2015 |
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Nausea; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2016 |
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Benzazepines; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2016 |
Daclatasvir for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2015 |
Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2016 |
The safety of daclatasvir for the treatment of hepatitis C.
Topics: Administration, Oral; Animals; Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Valine; Virus Replication | 2015 |
Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine | 2015 |
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Models, Theoretical; Pyrrolidines; Simeprevir; Sofosbuvir; Valine | 2016 |
Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Valine | 2016 |
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Odds Ratio; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Valine | 2016 |
[Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Immunoassay; Immunosuppressive Agents; Interferons; Interleukins; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ritonavir; Rituximab; Sensitivity and Specificity; Sulfonamides; Transfusion Reaction; Valine; Virus Activation | 2016 |
Daclatasvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
HCV NS5A replication complex inhibitors.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Design; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2016 |
A Review of Daclatasvir Drug-Drug Interactions.
Topics: Antiviral Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine | 2016 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Patient Selection; Pyrrolidines; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Valine | 2017 |
Hepatitis C: efficacy and safety in real life.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Cryoglobulinemia; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine | 2017 |
Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine | 2017 |
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Topics: Absorption, Physiological; Animals; Antiviral Agents; Biological Availability; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Drug Evaluation, Preclinical; Drug Interactions; Half-Life; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Tissue Distribution; Valine; Viral Nonstructural Proteins | 2018 |
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Pyrrolidines; Sulfonamides; Valine | 2018 |
Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Topics: Benzimidazoles; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2018 |
Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Economics, Medical; France; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Therapies, Investigational; Valine | 2019 |
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Tablets; Treatment Outcome; Valine | 2020 |
Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzofurans; Carbamates; Drug Therapy, Combination; Global Health; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Sofosbuvir; Sulfonamides; Uracil; Valine; World Health Organization | 2020 |
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
Topics: Adult; Aged; Antiviral Agents; Carbamates; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Imidazoles; Iran; Male; Middle Aged; Pyrrolidines; Randomized Controlled Trials as Topic; SARS-CoV-2; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.
Topics: Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Osteosclerosis; Pyrrolidines; Sofosbuvir; Valine | 2021 |
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine | 2021 |
Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials.
Topics: Antiviral Agents; Carbamates; COVID-19 Drug Treatment; Drug Therapy, Combination; Genotype; Hepacivirus; Humans; Imidazoles; Pyrrolidines; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome; Valine | 2022 |
112 trial(s) available for valine and bms-790052
| Article | Year |
|---|---|
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Topics: Adolescent; Adult; Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; Drug Resistance, Viral; Female; Genotype; HeLa Cells; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inhibitory Concentration 50; Male; Middle Aged; Pyrrolidines; Time Factors; Valine; Vero Cells; Viral Load; Viral Nonstructural Proteins; Young Adult | 2010 |
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.
Topics: Carbamates; Double-Blind Method; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Phenotype; Pyrrolidines; Replicon; RNA, Viral; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Double-Blind Method; Female; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; RNA, Viral; Valine; Viral Load; Viral Nonstructural Proteins | 2011 |
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Diarrhea; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Japan; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2012 |
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Valine | 2012 |
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; United States; Valine; Viral Load | 2012 |
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2013 |
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Valine | 2013 |
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Molecular Typing; Phenotype; Pyrrolidines; RNA, Viral; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
Topics: Adult; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Pilot Projects; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2014 |
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Contraceptives, Oral, Combined; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Monitoring; Ethinyl Estradiol; Female; Healthy Volunteers; Humans; Imidazoles; Norgestrel; Pyrrolidines; Valine; Young Adult | 2014 |
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2014 |
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Valine; Viral Load; Young Adult | 2014 |
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome; Valine; Viral Load | 2014 |
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine | 2014 |
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Topics: Adult; Aged; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Valine; Young Adult | 2014 |
Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Isoquinolines; Middle Aged; Mutant Proteins; Mutation, Missense; Pyrrolidines; Sulfonamides; Time Factors; Valine; Viral Nonstructural Proteins | 2015 |
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2014 |
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
Topics: Adolescent; Adult; Aged; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome; Valine; Viral Load; Young Adult | 2015 |
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Topics: Adult; Antiviral Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Young Adult | 2014 |
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Valine | 2015 |
In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
Topics: 5' Untranslated Regions; Antiviral Agents; Carbamates; Cyclohexanols; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Macrocyclic Compounds; MicroRNAs; Molecular Targeted Therapy; Mutation; Oligonucleotides; Oligopeptides; Pyrrolidines; Quinolines; Replicon; Thiazoles; Thiophenes; Valine | 2015 |
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
Topics: Adult; Antiviral Agents; Benzazepines; Carbamates; Drug Monitoring; Drug Resistance, Viral; Enzyme Inhibitors; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine | 2015 |
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Time Factors; Uridine Monophosphate; Valine; Young Adult | 2015 |
Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.
Topics: Antiviral Agents; Carbamates; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2015 |
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2015 |
Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
Topics: Administration, Oral; Adult; Antiviral Agents; Asian People; Carbamates; Double-Blind Method; Drug Administration Schedule; Healthy Volunteers; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Models, Biological; Pyrrolidines; Sulfonamides; Valine; Young Adult | 2015 |
An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects.
Topics: Adolescent; Adult; Carbamates; Cyclosporine; Drug Interactions; Female; Healthy Volunteers; Humans; Imidazoles; Immunosuppressive Agents; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Tacrolimus; Valine; Young Adult | 2015 |
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2015 |
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Valine; Viral Load | 2015 |
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2015 |
High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
Topics: Antiviral Agents; Carbamates; Coinfection; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Treatment Outcome; Valine | 2015 |
[Healing rate after 12 weeks over 90% for the first time].
Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine | 2015 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2015 |
[In Process Citation].
Topics: Anti-HIV Agents; Antiviral Agents; Carbamates; Cost Savings; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine; Viral Load | 2015 |
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Load | 2015 |
Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; Cytokines; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Killer Cells, Natural; Middle Aged; Pyrrolidines; Receptors, Immunologic; RNA, Viral; Sulfonamides; T-Lymphocytes; Valine; Viral Load | 2016 |
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2016 |
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Treatment Outcome; Valine | 2016 |
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
Topics: Alanine Transaminase; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; International Cooperation; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine | 2016 |
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2016 |
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Valine | 2016 |
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Sulfonamides; Treatment Outcome; Valine | 2016 |
[Complication sequelae prevented, morbidity decreased].
Topics: Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Sofosbuvir; Valine; Viremia | 2015 |
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; Carbamates; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; International Cooperation; Isoquinolines; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Load; Viral Nonstructural Proteins | 2016 |
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
[Daclatasvir/sofosbuvir is effective also in advanced liver disease].
Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; United States; Valine; Viral Load; Young Adult | 2016 |
Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Mutation; Pyrrolidines; Simeprevir; Sulfonamides; Treatment Failure; Treatment Outcome; Valine | 2017 |
[In HIV-HCV co-infection check for drug interactions].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine; Young Adult | 2016 |
Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Valine; Young Adult | 2016 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2016 |
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Humans; Imidazoles; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Piperazines; Pyridones; Pyrrolidines; Valine; Young Adult | 2016 |
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzazepines; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; RNA, Viral; Valine; Viral Nonstructural Proteins; Virus Replication | 2016 |
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult | 2017 |
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Tacrolimus; Transaminases; Valine | 2016 |
Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Female; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ritonavir; Valine; Young Adult | 2017 |
Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Simeprevir; Sofosbuvir; Treatment Outcome; United States; Valine | 2017 |
Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2017 |
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Proof of Concept Study; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Topics: Adult; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; Valine; Viral Load; Young Adult | 2017 |
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
Topics: Antiviral Agents; Bayes Theorem; Carbamates; Cohort Studies; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Recurrence; RNA, Viral; Simeprevir; Sustained Virologic Response; Valine; Young Adult | 2017 |
The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Logistic Models; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2017 |
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Outcome; Valine; Young Adult | 2017 |
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
Topics: Adult; Aged; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Interferons; Male; Middle Aged; Pyrrolidines; Ribavirin; Treatment Outcome; Valine; Viral Load | 2017 |
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Tacrolimus; Treatment Outcome; Valine; Viral Load | 2017 |
Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glucose Tolerance Test; Healthy Volunteers; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Imidazoles; Insulin; Lactic Acid; Male; Metformin; Middle Aged; Octamer Transcription Factor-1; Organic Cation Transporter 2; Pyrrolidines; Therapeutic Equivalency; Valine; Young Adult | 2017 |
Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load | 2017 |
Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pilot Projects; Prospective Studies; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
Topics: Adolescent; Adult; Benzazepines; Carbamates; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Healthy Volunteers; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pharmaceutical Preparations; Pyrrolidines; Sulfonamides; Valine; Young Adult | 2018 |
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kinetics; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins | 2018 |
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine; Viral Load | 2018 |
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Young Adult | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2018 |
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine | 2018 |
Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Models, Biological; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Carbamates; Cohort Studies; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Methadone; Middle Aged; Prospective Studies; Pyrrolidines; Valine | 2018 |
Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Membrane Glycoproteins; Middle Aged; Protease Inhibitors; Protein Isoforms; Pyrrolidines; Retrospective Studies; Sulfonamides; Valine; Young Adult | 2018 |
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Taiwan; Valine; Viral Nonstructural Proteins | 2019 |
Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
Topics: Adult; Aged; Amino Acid Substitution; Benzazepines; Carbamates; Drug Combinations; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Logistic Models; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Topics: Aged; Brazil; Carbamates; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Mutation; Pyrrolidines; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2019 |
An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Ill-Housed Persons; Imidazoles; Iran; Male; Middle Aged; Prevalence; Pyrrolidines; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2019 |
SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Iran; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tablets; Treatment Outcome; Valine | 2020 |
Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial.
Topics: Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Outcome and Process Assessment, Health Care; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Valine | 2019 |
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inflammation; Insulin Resistance; Interleukin-1beta; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life exp
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2020 |
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Vietnam | 2020 |
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Outcome Assessment, Health Care; Pharmacists; Pyrrolidines; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2020 |
[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Carbamates; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Leucine; Middle Aged; Proline; Pyrrolidines; Ritonavir; Russia; Sulfones; Treatment Outcome; Urea; Valine | 2019 |
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Hospitalization; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Patient Admission; Pneumonia, Viral; Pyrrolidines; SARS-CoV-2; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2020 |
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Topics: Adult; Ambulatory Care; Antimalarials; Antiviral Agents; Carbamates; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.
Topics: Antiviral Agents; Carbamates; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Humans; Imidazoles; Length of Stay; Prospective Studies; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2022 |
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Genotype; Humans; Imidazoles; Intensive Care Units; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER).
Topics: Adult; Antiviral Agents; Carbamates; COVID-19; Humans; Imidazoles; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine | 2022 |
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study.
Topics: Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Treatment Outcome; Valine | 2022 |
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Topics: Antiviral Agents; Carbamates; COVID-19; Humans; Imidazoles; Nitro Compounds; Pyrrolidines; SARS-CoV-2; Sofosbuvir; South Africa; Thiazoles; Treatment Outcome; Valine | 2022 |
484 other study(ies) available for valine and bms-790052
| Article | Year |
|---|---|
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Imidazoles; Mutation; Phenotype; Pyrrolidines; Valine | 2010 |
Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genotype; Hepacivirus; High-Throughput Screening Assays; Humans; Imidazoles; Interferon-alpha; Mutation; Phenotype; Pyrrolidines; Recombinant Proteins; Time Factors; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
[BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
Topics: Antiviral Agents; Carbamates; Germany; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; RNA, Viral; Valine | 2011 |
Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Endoplasmic Reticulum; Hepacivirus; Hepatocytes; Humans; Imidazoles; Inhibitory Concentration 50; Lipids; Microscopy, Confocal; Models, Molecular; Pyrrolidines; Replicon; Small Molecule Libraries; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein.
Topics: Antiviral Agents; Carbamates; Cell Line; Hepacivirus; Hepatocytes; Humans; Imidazoles; Protein Binding; Protein Transport; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.
Topics: Alanine; Antiviral Agents; Carbamates; Cell Line; Chromatography, High Pressure Liquid; Diarrhea Viruses, Bovine Viral; Drug Discovery; Drug Resistance, Viral; Hepacivirus; Humans; Imidazoles; Mass Spectrometry; Nuclear Magnetic Resonance, Biomolecular; Proline; Pyrrolidines; Stilbenes; Thiazolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.
Topics: Base Sequence; Carbamates; Cell Line, Tumor; DNA Primers; Hepacivirus; Humans; Imidazoles; Mutation; Phosphorylation; Pyrrolidines; RNA, Viral; Valine; Viral Nonstructural Proteins | 2011 |
Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Hepacivirus; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Assembly | 2011 |
A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma.
Topics: Animals; Antiviral Agents; Carbamates; Chromatography, Liquid; Dogs; Drug Stability; Drugs, Investigational; Female; Haplorhini; Imidazoles; Linear Models; Male; Mice; Pyrrolidines; Rabbits; Rats; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Valine; Viral Nonstructural Proteins | 2011 |
The end of the beginning for hepatitis C treatment.
Topics: Antiviral Agents; Carbamates; Enzyme Inhibitors; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine; Viral Nonstructural Proteins | 2012 |
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Cell Line; Drug Resistance, Viral; Genes, Reporter; Genotype; Hepacivirus; Humans; Imidazoles; Inhibitory Concentration 50; Luciferases; Molecular Sequence Data; Pyrrolidines; Replicon; Valine; Viral Nonstructural Proteins; Virus Replication | 2012 |
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.
Topics: Antiviral Agents; Carbamates; Cell Line; Drug Resistance, Viral; Genotype; Humans; Imidazoles; Polymorphism, Genetic; Pyrrolidines; RNA, Viral; Valine; Viral Nonstructural Proteins | 2012 |
A watershed moment in the treatment of hepatitis C.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Valine | 2012 |
Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Inhibitory Concentration 50; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prevalence; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2012 |
Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
Topics: Biological Availability; Carbamates; Carbon Isotopes; Chromatography, Liquid; Flow Injection Analysis; Humans; Imidazoles; Nitrogen Isotopes; Oxadiazoles; Pyrrolidines; Reference Standards; Sulfonamides; Tandem Mass Spectrometry; Valine | 2012 |
A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.
Topics: Carbamates; Chromatography, Liquid; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liquid-Liquid Extraction; Pyrrolidines; Sensitivity and Specificity; Tandem Mass Spectrometry; Valine; Viral Nonstructural Proteins | 2012 |
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Molecular Sequence Data; Prevalence; Protease Inhibitors; Pyrrolidines; Sequence Analysis, DNA; Valine; Viral Nonstructural Proteins; Young Adult | 2012 |
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cholestasis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load | 2012 |
NS5A inhibitors to treat hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Valine | 2012 |
Correlation between NS5A dimerization and hepatitis C virus replication.
Topics: Carbamates; Cyclophilin A; Hepacivirus; Humans; Imidazoles; Protein Multimerization; Protein Structure, Tertiary; Pyrrolidines; RNA, Viral; Valine; Viral Nonstructural Proteins; Virus Replication | 2012 |
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.
Topics: Antiviral Agents; Benzazepines; Carbamates; Cell Line; Drug Interactions; Drug Resistance, Viral; Hepacivirus; Humans; Imidazoles; Indoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2012 |
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.
Topics: Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Imidazoles; Molecular Structure; Proline; Pyrrolidines; Stilbenes; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins; Virus Replication | 2012 |
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.
Topics: Amino Acid Sequence; Amino Acid Substitution; Amino Acids; Antiviral Agents; Carbamates; Genotype; Hepacivirus; Imidazoles; Molecular Sequence Data; Pyrrolidines; Reassortant Viruses; Replicon; Valine; Viral Nonstructural Proteins | 2013 |
Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Congresses as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Interleukins; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins | 2013 |
Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.
Topics: Administration, Intravenous; Biological Availability; Carbamates; Drug Design; Humans; Imidazoles; Isotope Labeling; Mass Spectrometry; Pyrrolidines; Reproducibility of Results; Valine | 2012 |
Calamitous HCV trial casts shadow over nucleoside drugs.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Heart Diseases; Humans; Imidazoles; Kidney Diseases; Nucleosides; Patient Selection; Pyrrolidines; Valine | 2012 |
Daclatasvir: a promising triple therapy for children with chronic hepatitis C.
Topics: Adolescent; Carbamates; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Multicenter Studies as Topic; Pyrrolidines; Randomized Controlled Trials as Topic; Valine | 2013 |
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Imidazoles; Inhibitory Concentration 50; Molecular Structure; Proline; Pyrrolidines; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Topics: 3' Untranslated Regions; Amino Acid Substitution; Carbamates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; Hepacivirus; Hepatocytes; Humans; Imidazoles; Isoquinolines; Mutation; Protease Inhibitors; Pyrrolidines; Recombination, Genetic; Sulfonamides; Valine; Viral Nonstructural Proteins | 2013 |
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatocytes; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Protein Isoforms; Pyrrolidines; Recombinant Proteins; Replicon; Sulfonamides; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Interferon free regimens for the "difficult-to-treat": are we there?
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2013 |
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2013 |
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
Topics: Adult; Antiviral Agents; Bayes Theorem; Carbamates; Cell Line; Deoxycytidine; Female; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Models, Biological; Pyrrolidines; RNA, Viral; Valine; Viral Load; Viral Nonstructural Proteins; Virus Assembly | 2013 |
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Hepacivirus; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Pyrrolidines; Structure-Activity Relationship; Valine; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2013 |
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Topics: Carbamates; Cholestasis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; RNA, Viral; Sofosbuvir; Transplantation, Homologous; Uridine Monophosphate; Valine | 2013 |
A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
Topics: Antiviral Agents; Carbamates; Cell Line; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Imidazoles; Luciferases; Microbial Sensitivity Tests; Pyrrolidines; Staining and Labeling; Valine; Virology; Virus Replication | 2013 |
Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2013 |
Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Synergism; Hepacivirus; Hepatocytes; Humans; Imidazoles; Macrocyclic Compounds; Pyrrolidines; Quinolines; Thiazoles; Time Factors; Valine; Viral Load; Virus Internalization; Virus Replication | 2013 |
The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.
Topics: Antiviral Agents; Carbamates; Enzyme Inhibitors; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Models, Biological; Pyrrolidines; Time Factors; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins | 2013 |
Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Hepacivirus; Humans; Imidazoles; Models, Theoretical; Plasma; Pyrrolidines; Valine; Viral Load | 2014 |
Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Genotype; Hepacivirus; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Liver; Liver Neoplasms; Mutation; Oligopeptides; Proline; Protease Inhibitors; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
"There are decades where nothing happens; and there are weeks where decades happen"--Vladimir Ilyich Lenin.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2014 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Phenotype; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Treatment Outcome; Valine; Viral Load; Young Adult | 2014 |
Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
Topics: Animals; Antiviral Agents; Area Under Curve; Carbamates; Dogs; Drug Discovery; Enzyme Inhibitors; Hepacivirus; Imidazoles; Magnetic Resonance Spectroscopy; Pyrrolidines; Rats; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
Topics: Antiviral Agents; Carbamates; Codon; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Mutation Rate; Polymorphism, Genetic; Pyrrolidines; Retrospective Studies; Sequence Analysis, RNA; Valine; Viral Nonstructural Proteins | 2015 |
The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors.
Topics: Antiviral Agents; Carbamates; Crystallography, X-Ray; Drug Resistance, Viral; Genotype; Hepacivirus; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.
Topics: Carbamates; Cell Line; Drug Resistance, Viral; Gene Expression Profiling; Genetic Fitness; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes.
Topics: Algorithms; Antiviral Agents; Binding Sites; Carbamates; Cluster Analysis; Computer Simulation; Drug Resistance, Viral; Genotype; Imidazoles; Models, Molecular; Molecular Docking Simulation; Mutation; Pyrrolidines; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins | 2015 |
HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyper-IgM Immunodeficiency Syndrome; Imidazoles; Immunoglobulin M; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine | 2014 |
Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.
Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Imidazoles; Pyrrolidines; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins | 2014 |
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Topics: Antibodies, Neutralizing; Antiviral Agents; Carbamates; Cell Communication; Cells, Cultured; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Oligopeptides; Proline; Pyrrolidines; Valine; Viral Load; Virus Internalization | 2014 |
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides.
Topics: Antiviral Agents; Biological Transport; Carbamates; Gene Expression; HEK293 Cells; Hepacivirus; Heterocyclic Compounds, 3-Ring; Host-Pathogen Interactions; Humans; Imidazoles; Isoquinolines; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Plasmids; Pyrrolidines; Recombinant Proteins; Simeprevir; Sofosbuvir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Transfection; Uridine Monophosphate; Valine | 2014 |
Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Hepacivirus; Imidazoles; Protease Inhibitors; Pyrrolidines; Replicon; Valine; Viral Nonstructural Proteins | 2014 |
Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Topics: Antiviral Agents; Binding Sites; Carbamates; Cell Line, Tumor; Cell Membrane; Drug Design; Drug Resistance, Viral; Hepacivirus; Hepatocytes; Host-Pathogen Interactions; Humans; Imidazoles; Minor Histocompatibility Antigens; Molecular Docking Simulation; Molecular Structure; Mutation; Phosphotransferases (Alcohol Group Acceptor); Protease Inhibitors; Protein Conformation; Protein Multimerization; Pyrrolidines; Structure-Activity Relationship; Time Factors; Transfection; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C beware--the end is nigh.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2014 |
Daclatasvir + asunaprevir: first global approval.
Topics: Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; Drug Design; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Pyrrolidines; Sulfonamides; Valine | 2014 |
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indoles; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins | 2015 |
HCV NS5A inhibitors disrupt replication factory formation: a novel mechanism of antiviral action.
Topics: Antiviral Agents; Carbamates; Cell Membrane; Hepacivirus; Hepatocytes; Humans; Imidazoles; Protease Inhibitors; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
[New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
Topics: Antiviral Agents; Carbamates; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins | 2014 |
Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir.
Topics: Carbamates; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2015 |
Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.
Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Hepacivirus; Imidazoles; Molecular Docking Simulation; Pyrrolidines; Sequence Alignment; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Topics: Antiviral Agents; Carbamates; Cell Line; Hepacivirus; Hepatitis C; Humans; Imidazoles; Minor Histocompatibility Antigens; Phosphatidylinositols; Phosphotransferases (Alcohol Group Acceptor); Protein Binding; Protein Transport; Pyrrolidines; RNA-Dependent RNA Polymerase; Valine; Viral Nonstructural Proteins; Virus Replication | 2015 |
Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.
Topics: Antiviral Agents; Benzazepines; Carbamates; Chromatography, Liquid; Hepacivirus; Humans; Imidazoles; Indoles; Interferons; Isoquinolines; Plasma; Pyrrolidines; Reproducibility of Results; Ribavirin; Sulfonamides; Tandem Mass Spectrometry; Valine | 2015 |
[Interferon-free treatment for patients with chronic hepatitis C].
Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Protease Inhibitors; Pyrrolidines; Sulfonamides; Valine | 2015 |
[Direct-acting antiviral-resistant variant].
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Protease Inhibitors; Pyrrolidines; Valine | 2015 |
[Pharmacological properties and clinical efficacy of daclatasvir (Daklinza®) and asunaprevir (Sunvepra®)].
Topics: Administration, Oral; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2015 |
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Japan; Pyrrolidines; Sequence Analysis, DNA; Valine; Viral Nonstructural Proteins | 2015 |
A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Fluorescent Antibody Technique; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load; Virus Replication | 2015 |
HIV-hepatitis C co-infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Pyrrolidines; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA].
Topics: Anti-HIV Agents; Carbamates; Drug Combinations; Gastroenterology; Germany; Hepatitis C; Imidazoles; Internal Medicine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Imidazoles; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Imidazoles; Mutation, Missense; Phylogeny; Polymerase Chain Reaction; Polymorphism, Genetic; Prevalence; Protease Inhibitors; Pyrrolidines; Sequence Analysis; Sweden; Valine; Viral Nonstructural Proteins | 2015 |
Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Middle Aged; Pyrrolidines; Ribavirin; Treatment Failure; Valine; Viral Load; Viral Nonstructural Proteins | 2015 |
Continued progress against hepatitis C infection.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Pyrrolidines; Sulfonamides; Valine | 2015 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Valine; Viral Load; Viremia | 2015 |
Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.
Topics: Anticholesteremic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Hepacivirus; Hepatocytes; Host-Pathogen Interactions; Humans; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Imidazoles; Indoles; Oligopeptides; Pyrrolidines; Replicon; Signal Transduction; Valine; Viral Proteins; Virus Replication | 2015 |
Thousands of patients in England to get new hepatitis C drugs.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; England; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication.
Topics: Amides; Animals; Antiviral Agents; Carbamates; Drug Design; Half-Life; Hepacivirus; Humans; Hydrogen; Imidazoles; Nitrogen; Prodrugs; Pyrrolidines; Rats; Valine; Virus Replication | 2015 |
Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line; Chemistry Techniques, Synthetic; Chlorocebus aethiops; Drug Design; Drug Evaluation, Preclinical; Hepacivirus; Humans; Imidazoles; Molecular Targeted Therapy; Mutation; Pyrrolidines; Structure-Activity Relationship; Valine; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2015 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Valine; Viral Load; Virus Activation | 2015 |
Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Biomarkers; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Retreatment; Sulfonamides; Time Factors; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins | 2016 |
Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Carbamates; Drug Interactions; Imidazoles; Methadone; Pyrrolidines; Valine | 2015 |
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Liver Cirrhosis; Middle Aged; Phosphoproteins; Polymorphism, Genetic; Pyrrolidines; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult | 2015 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2015 |
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Gene Expression Regulation, Viral; Genotype; Global Health; Hepacivirus; Hepatitis C; Humans; Imidazoles; Phylogeny; Polymorphism, Genetic; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2016 |
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Multiple, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Viral, Animal; Hepatocytes; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Transplantation Chimera; Treatment Failure; Valine | 2015 |
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Ultrasonography; Uridine Monophosphate; Valine | 2015 |
Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
Topics: Antiviral Agents; Biomarkers; Carbamates; Cell Line, Tumor; Dendritic Cells; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Isoquinolines; Liver Transplantation; Prednisolone; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.
Topics: Amiodarone; Antiviral Agents; Bradycardia; Carbamates; Drug Therapy, Combination; Electrocardiography; Female; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Time Factors; Valine; Vasodilator Agents | 2015 |
Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Sampling Studies; Sulfonamides; Tacrolimus; Valine | 2016 |
Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Serum Albumin; Sulfonamides; Valine; Viral Load | 2016 |
Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Markov Chains; Middle Aged; Pyrrolidines; Quality-Adjusted Life Years; Simeprevir; Valine | 2016 |
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Standard of Care; Treatment Outcome; Valine | 2016 |
Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Failure; Liver Transplantation; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine; Virus Activation | 2015 |
Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
Topics: Antiviral Agents; Carbamates; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation, Viral; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Imidazoles; Liver; Models, Statistical; Protease Inhibitors; Pyrrolidines; RNA, Viral; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2016 |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Simeprevir; Valine | 2015 |
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Topics: Adult; Aged; Antiviral Agents; Canada; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Markov Chains; Middle Aged; Pyrrolidines; Quality-Adjusted Life Years; Sofosbuvir; Valine | 2016 |
Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
Topics: Antiviral Agents; Benzazepines; Carbamates; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunologic Memory; Indoles; Isoquinolines; Killer Cells, Natural; Lymphocyte Activation; Pyrrolidines; Receptors, Immunologic; Sulfonamides; Valine; Viral Load | 2015 |
Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Topics: Allosteric Regulation; Animals; Antiviral Agents; Biphenyl Compounds; Carbamates; Cell Line; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Mice; Models, Molecular; Protein Conformation; Protein Multimerization; Protein Structure, Quaternary; Pyrrolidines; Reproducibility of Results; Valine; Viral Nonstructural Proteins; Virus Replication | 2015 |
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.
Topics: Antiviral Agents; Carbamates; Chile; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Probability; Protease Inhibitors; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
Topics: Antiviral Agents; Carbamates; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Markov Chains; Models, Economic; Phenotype; Protease Inhibitors; Pyrrolidines; Time Factors; Treatment Outcome; United Kingdom; Valine | 2016 |
Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Carbamates; Chimera; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Isoquinolines; Mice; Mutation; Pyrrolidines; Sulfonamides; Valine | 2016 |
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Valine; Viral Load | 2015 |
Synergistic Activity of Combined NS5A Inhibitors.
Topics: Antiviral Agents; Biphenyl Compounds; Carbamates; Cell Line; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Humans; Imidazoles; Molecular Docking Simulation; Pyrrolidines; Replicon; Valine; Viral Nonstructural Proteins; Virus Replication | 2015 |
Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Phosphorylation; Pyrrolidines; Retreatment; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Sulfonamides; Sustained Virologic Response; TNF-Related Apoptosis-Inducing Ligand; Valine; Viral Load | 2017 |
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; Renal Insufficiency; Sulfonamides; Valine | 2016 |
The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2016 |
Ceftazidime pentahydrate/avibactam sodium, Isavuconazonium sulfate, and Daclatasvir dihydrochloride.
Topics: Anti-Infective Agents; Azabicyclo Compounds; Carbamates; Ceftazidime; Drug Combinations; Humans; Imidazoles; Nitriles; Prodrugs; Pyridines; Pyrrolidines; Triazoles; Valine | 2016 |
Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Mutation, Missense; Nucleic Acid Amplification Techniques; Pyrrolidines; RNA, Viral; Sequence Analysis, DNA; Sofosbuvir; Valine | 2016 |
[Daclatasvir plus asunaprevir combination therapy for patients with chronic hepatitis C].
Topics: Carbamates; Clinical Trials as Topic; Combined Modality Therapy; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine | 2015 |
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Failure; Valine; Viral Load | 2016 |
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Retrospective Studies; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Valine | 2016 |
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Synthesis of isotopically labeled daclatasvir for use in human clinical studies.
Topics: Biological Availability; Carbamates; Chemistry Techniques, Synthetic; Humans; Imidazoles; Isotope Labeling; Pyrrolidines; RNA-Dependent RNA Polymerase; Teprotide; Valine; Viral Nonstructural Proteins | 2016 |
Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Interactions; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2016 |
Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Iron Deficiencies; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2016 |
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Viral Load; Young Adult | 2016 |
Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and Rearrangement.
Topics: Animals; Bile; Biotransformation; Carbamates; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dogs; Haplorhini; Hepatocytes; Humans; Imidazoles; Macaca fascicularis; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Microsomes, Liver; Oxidation-Reduction; Pyrrolidines; Rats; Rats, Sprague-Dawley; Valine | 2016 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Renal Dialysis; RNA, Viral; Sulfonamides; Valine | 2016 |
Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lung Diseases; Male; Middle Aged; Prednisolone; Pyrrolidines; Radiography, Thoracic; Sulfonamides; Tomography, X-Ray Computed; Valine | 2016 |
Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pruritus; Pyrrolidines; Recurrence; Simeprevir; Sleep Initiation and Maintenance Disorders; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2016 |
Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
Topics: Anti-HIV Agents; Antiviral Agents; Area Under Curve; Carbamates; Coinfection; Darunavir; Diuretics; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidines; Renal Insufficiency; Ritonavir; Treatment Outcome; Valine | 2016 |
Sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2016 |
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Kidney; Kidney Function Tests; Kidney Transplantation; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Pyrrolidines; Renal Dialysis; Renal Insufficiency; RNA, Viral; Simeprevir; Sofosbuvir; Valine | 2016 |
Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Topics: Algorithms; Antiviral Agents; Benzazepines; Biotransformation; Carbamates; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Hepatocytes; Humans; Imidazoles; Indoles; Isoquinolines; Kinetics; Liver; Midazolam; Models, Biological; Nonlinear Dynamics; Pyrrolidines; Risk Assessment; Risk Factors; RNA, Messenger; Sulfonamides; Valine | 2016 |
Development and validation of sensitive and rapid UPLC-MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Humans; Imidazoles; Limit of Detection; Plasma; Pyrrolidines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Therapeutic Equivalency; Valine | 2016 |
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Directly Observed Therapy; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Substance Abuse Treatment Centers; Valine | 2016 |
Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Asian People; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
New drugs 2016, part 2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzimidazoles; Carbamates; Drug Approval; Drug Therapy; Humans; Imidazoles; Nitriles; Pyridines; Pyrrolidines; Quinolones; Thiophenes; Triazoles; United States; United States Food and Drug Administration; Valine | 2016 |
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Valine; Viral Nonstructural Proteins | 2016 |
Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult | 2016 |
Successful treatment of hepatitis C virus infection combining daclatasvir and simeprevir in a heart transplant recipient with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Heart Transplantation; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Simeprevir; Valine | 2016 |
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
Topics: Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
Topics: Acute Disease; Aged, 80 and over; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine; Virus Activation | 2016 |
Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Prospective Studies; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sulfonamides; Treatment Outcome; Valine | 2016 |
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.
Topics: Antiviral Agents; Austria; Benzimidazoles; Carbamates; Coinfection; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Quality of Life; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Topics: Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carbamates; Carcinoma, Hepatocellular; Carrier Proteins; Early Diagnosis; Female; Glycoproteins; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Membrane Glycoproteins; Plant Lectins; Pyrrolidines; Sulfonamides; Valine | 2016 |
Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease".
Topics: Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
Topics: Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
Topics: Aged; Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Female; France; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2016 |
Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2017 |
Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine.
Topics: Anticonvulsants; Antiviral Agents; Carbamates; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Epilepsy; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Oxcarbazepine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Renal Dialysis; Sulfonamides; Treatment Outcome; Valine | 2017 |
Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report.
Topics: Adult; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Perioperative Care; Pyrrolidines; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2016 |
[Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report].
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine | 2016 |
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Compassionate Use Trials; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Failure; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Mutation, Missense; Polymorphism, Genetic; Pyrrolidines; Sustained Virologic Response; Treatment Outcome; United States; Valine; Viral Nonstructural Proteins | 2016 |
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
Topics: Animals; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Interferons; Isoquinolines; Mice, SCID; Protease Inhibitors; Pyrrolidines; Simeprevir; Sulfonamides; Treatment Failure; Valine | 2016 |
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Industry; Drug Therapy, Combination; Fees, Pharmaceutical; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Quality Assurance, Health Care; Quality Control; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2016 |
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon Type I; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Pyrrolidines; Ribavirin; Risk Factors; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Lung Injury; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Pyrrolidines; Retrospective Studies; Ribavirin; San Francisco; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Vulnerable Populations; Young Adult | 2016 |
A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir.
Topics: Carbamates; Drug Eruptions; Erythema Multiforme; Humans; Imidazoles; Male; Middle Aged; Psoriasis; Pyrrolidines; Sofosbuvir; Valine | 2017 |
Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2017 |
Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Kidney; Longitudinal Studies; Male; Pyrrolidines; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2017 |
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
Topics: Aged; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine | 2016 |
Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity.
Topics: Alanine; Antiviral Agents; Azepines; Carbamates; Cell Line; Cell Survival; Cells, Cultured; Drug Synergism; Gene Expression Regulation; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Imidazoles; Oxidative Stress; Presenilins; Proteolysis; Pyrrolidines; Reactive Oxygen Species; Valine; Viral Core Proteins; Virus Replication | 2016 |
Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Base Sequence; Carbamates; China; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA Helicases; Sequence Analysis, DNA; Serine Endopeptidases; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2017 |
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Valine | 2017 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine | 2016 |
Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Genome, Viral; Hepacivirus; Humans; Imidazoles; Protein Transport; Pyrrolidines; RNA Transport; RNA, Viral; Valine; Viral Core Proteins; Viral Envelope Proteins; Viral Nonstructural Proteins; Virus Assembly | 2017 |
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
Topics: Antiviral Agents; Carbamates; Computational Biology; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phosphoproteins; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2016 |
Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma.
Topics: Carbamates; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Storage; Hepacivirus; Humans; Imidazoles; Pyrrolidines; Reproducibility of Results; Ultraviolet Rays; Valine | 2017 |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction.
Topics: Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Imidazoles; Isoquinolines; Japan; Pyrrolidines; Renal Insufficiency; Sulfonamides; Treatment Outcome; Valine | 2017 |
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Topics: Adenosine; Antiviral Agents; Carbamates; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Mutation; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2017 |
Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sulfonamides; Taiwan; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Carbamates; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Phylogeny; Pyrrolidines; Serotyping; Sulfonamides; Time Factors; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sex Factors; Sulfonamides; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
Topics: Animals; Anti-Retroviral Agents; Carbamates; Drug Resistance, Viral; Evolution, Molecular; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Mice; Mutation; Phylogeny; Pyrrolidines; Selection, Genetic; Sulfonamides; Valine | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Hepatitis C; Imidazoles; Limit of Detection; Pharmaceutical Solutions; Pyrrolidines; Reproducibility of Results; Tablets; Valine | 2017 |
Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Severity of Illness Index; Sulfonamides; Treatment Outcome; Valine | 2017 |
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sweden; Treatment Outcome; Valine | 2017 |
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Topics: Aged; Antiviral Agents; B-Lymphocyte Subsets; Biomarkers; Carbamates; Case-Control Studies; Cryoglobulinemia; Cytokines; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis Viruses; Humans; Imidazoles; Immune Tolerance; Immunity, Cellular; Male; Middle Aged; Phenotype; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; T-Lymphocyte Subsets; Time Factors; Treatment Outcome; Valine; Vasculitis; Viral Load | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
Topics: Antiviral Agents; B-Lymphocytes; Carbamates; CD4-Positive T-Lymphocytes; Cryoglobulinemia; Cryoglobulins; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Immunoglobulin M; Interleukins; Lymphocyte Count; Male; Middle Aged; Prospective Studies; Pyrrolidines; Receptors, Complement 3d; Receptors, CXCR5; Sofosbuvir; Sustained Virologic Response; T-Lymphocytes, Regulatory; Th17 Cells; Valine; Vasculitis | 2017 |
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Markov Chains; Middle Aged; Models, Economic; Pyrrolidines; Quality-Adjusted Life Years; Sofosbuvir; Survival Analysis; United States; Valine | 2017 |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; RNA, Viral; Sulfonamides; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Male; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2017 |
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine | 2017 |
A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Combinations; Drug Discovery; Drug Resistance, Viral; Drug Synergism; Gene Expression; Hepacivirus; Hepatocytes; High-Throughput Screening Assays; Host-Pathogen Interactions; Humans; Imidazoles; Interferon-alpha; Oligopeptides; Primary Cell Culture; Pyridines; Pyrimidines; Pyrrolidines; Sofosbuvir; Valine; Viral Envelope Proteins; Virion; Virus Internalization; Virus Release | 2017 |
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Macrocyclic Compounds; Male; Patient Participation; Patient-Centered Care; Prospective Studies; Pyrrolidines; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2017 |
Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Carbamates; Creatinine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Nephritis, Interstitial; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Time Factors; Valine | 2017 |
Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
Topics: Antiviral Agents; Carbamates; Coinfection; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Treatment Outcome; Valine; Viral Load | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Carbamates; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Russia; Sulfonamides; Taiwan; Treatment Outcome; Valine; Young Adult | 2017 |
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
Topics: Aged; Aged, 80 and over; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Linear Models; Lipid Metabolism; Lipids; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2017 |
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
Topics: Adult; Antiviral Agents; beta-Thalassemia; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Simeprevir; Sofosbuvir; Valine | 2017 |
Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Pyrrolidines; Sequence Analysis; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2018 |
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Serine Proteases; Simeprevir; Sulfonamides; Time Factors; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Retrospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferons; Isoquinolines; Kidney Transplantation; Male; Middle Aged; Prednisolone; Prospective Studies; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine | 2017 |
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Retrospective Studies; Spain; Sustained Virologic Response; Valine | 2017 |
Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Belgian experience with direct acting antivirals in people who inject drugs.
Topics: Adult; Aged; Antiviral Agents; Belgium; Carbamates; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Simeprevir; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2017 |
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2017 |
The elderly and direct antiviral agents: Constraint or challenge?
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Logistic Models; Male; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2017 |
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Scandinavian and Nordic Countries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702.
Topics: Carbamates; Cost-Benefit Analysis; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; United States; Valine | 2017 |
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Topics: Carbamates; Cost-Benefit Analysis; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; United States; Valine | 2017 |
Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genetic Diseases, Inborn; Hemorrhage; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Hepatobiliary and Pancreatic: Rare vascular tumor following treatment for hepatitis C with direct-acting antivirals.
Topics: Aged, 80 and over; Antiviral Agents; Carbamates; Fatal Outcome; Female; Hemangioendothelioma, Epithelioid; Hepatitis C; Humans; Imidazoles; Liver Neoplasms; Palliative Care; Pyrrolidines; Valine | 2017 |
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Proportional Hazards Models; Pyrrolidines; Ribavirin; Risk Factors; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2017 |
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Base Sequence; Carbamates; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Prevalence; Pyrrolidines; Republic of Korea; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Valine; Young Adult | 2017 |
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2017 |
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
Topics: Adult; Aged; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Japan; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prognosis; Protease Inhibitors; Pyrrolidines; Recurrence; Risk Factors; Sulfonamides; Valine | 2017 |
Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Drugs, Chinese Herbal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Humans; Hydrolyzable Tannins; Imidazoles; Mice; Mice, SCID; Paeonia; Plant Extracts; Pyrrolidines; Valine; Virion; Virus Attachment; Virus Replication | 2017 |
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2017 |
Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sustained Virologic Response; Valine; Viral Load; Young Adult | 2018 |
Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Drug Therapy, Combination; Egypt; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; International Normalized Ratio; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrrolidines; Ribavirin; Serum Albumin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Heart Transplantation; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Valine; Young Adult | 2018 |
Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
Topics: Aged; Animals; Antiviral Agents; Benzazepines; Carbamates; Disease Models, Animal; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Imidazoles; Immunity, Innate; Indoles; Inflammation; Isoquinolines; Liver; Male; Mice; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2017 |
Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrrolidines; Risk Factors; Sulfonamides; Sustained Virologic Response; Tomography, X-Ray Computed; Valine | 2017 |
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Insulin Resistance; Insulin-Secreting Cells; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2017 |
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Egypt; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Models, Statistical; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Uridine Monophosphate; Valine | 2017 |
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study.
Topics: Adult; Alleles; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatocyte Nuclear Factor 4; Humans; Imidazoles; Linear Models; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Pyrrolidines; Real-Time Polymerase Chain Reaction; Valine | 2017 |
MSF pushes down price of generic hepatitis C drugs to new low level.
Topics: Antiviral Agents; Carbamates; Developing Countries; Drug Costs; Drug Industry; Drugs, Generic; Hepatitis C, Chronic; Humans; Imidazoles; International Cooperation; Pyrrolidines; Sofosbuvir; Valine | 2017 |
Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Biomarkers; Carbamates; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Sulfonamides; Valine | 2018 |
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Everolimus; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Pyrrolidines; Sirolimus; Sofosbuvir; Valine; Virus Replication | 2018 |
Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Mutation, Missense; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2018 |
A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Phenotype; Pyrrolidines; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine | 2018 |
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine | 2018 |
Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
Topics: Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Valine | 2018 |
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kinetics; Pyrrolidines; Sulfonamides; Valine | 2017 |
Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.
Topics: Aged; Amino Acid Sequence; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Liver Cirrhosis; Phylogeny; Polymerase Chain Reaction; Pyrrolidines; Recurrence; RNA, Viral; Sequence Homology, Amino Acid; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Equatorial Guinea; Female; Fluorenes; Gene Expression; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Middle Aged; Mutation; Phylogeny; Proline; Pyrrolidines; Sequence Analysis, DNA; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2018 |
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno.
Topics: Antiviral Agents; Carbamates; Chile; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Public Health; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2017 |
Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Drug Utilization; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Young Adult | 2018 |
UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry; Valine | 2018 |
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sex Factors; Sulfonamides; Treatment Failure; Valine | 2018 |
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Molecular Conformation; Particle Size; Porosity; Pyrrolidines; Simeprevir; Sofosbuvir; Surface Properties; Valine | 2018 |
Self-association and conformational variation of NS5A domain 1 of hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Chromatography, Gel; Drug Resistance, Viral; Dynamic Light Scattering; Genotype; Hepacivirus; Imidazoles; Molecular Conformation; Protein Domains; Pyrrolidines; Scattering, Small Angle; Valine; Viral Nonstructural Proteins | 2018 |
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Topics: Adult; Antiviral Agents; Carbamates; Comorbidity; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Carbamates; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Valine | 2018 |
Case of psoriatic patient who maintains long-term remission after anti-hepatitis C virus agents and ustekinumab treatment.
Topics: Aged; Antiviral Agents; Carbamates; Dermatologic Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Psoriasis; Pyrrolidines; Remission Induction; RNA, Viral; Severity of Illness Index; Sulfonamides; Ustekinumab; Valine | 2018 |
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Valine | 2018 |
Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
Topics: Adult; Antiviral Agents; Carbamates; China; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Quality-Adjusted Life Years; Sulfonamides; Valine | 2018 |
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2019 |
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Benzazepines; Biopsy; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Glomerulonephritis; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2018 |
Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Chronic Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quality of Life; Sulfonamides; Treatment Outcome; Valine | 2018 |
Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia.
Topics: Aged, 80 and over; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney Diseases; Proteinuria; Pyrrolidines; Sulfonamides; Valine | 2018 |
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
Topics: Aged; Antibodies; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Peptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Seroepidemiologic Studies; Sofosbuvir; Valine; Viral Load | 2018 |
Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2018 |
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2018 |
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Topics: Adult; Antiviral Agents; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Markov Chains; Middle Aged; Monte Carlo Method; Polyethylene Glycols; Probability; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Valine | 2018 |
A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
Topics: Acute Disease; Adult; Carbamates; China; Drug Therapy, Combination; Early Diagnosis; Early Medical Intervention; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Tattooing; Valine | 2018 |
Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
Topics: Adult; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Female; Hepacivirus; Humans; Imidazoles; Limit of Detection; Linear Models; Male; Micelles; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Spectrophotometry, Ultraviolet; Valine | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult | 2018 |
Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?
Topics: Antiviral Agents; Benzimidazoles; Blood Glucose; Carbamates; Diabetes Mellitus; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Gene Expression; Hepatitis C; Humans; Imidazoles; Immunity, Innate; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Pyrrolidines; RNA, Messenger; Sulfonamides; Treatment Outcome; Valine | 2018 |
Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis.
Topics: Aged; Antiviral Agents; Carbamates; Etanercept; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Male; Psoriasis; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Tumor Necrosis Factor-alpha; Valine | 2018 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Hepatitis C; Humans; Imidazoles; Incidence; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2018 |
Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus.
Topics: Antiviral Agents; Biflavonoids; Carbamates; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drugs, Chinese Herbal; Flavonoids; Hepacivirus; Humans; Imidazoles; Phytotherapy; Pyrrolidines; Valine; Virus Internalization; Virus Replication | 2018 |
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
Topics: Aged; Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Mutation; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins; Virus Assembly; Virus Replication | 2018 |
Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children.
Topics: Adolescent; Antiviral Agents; beta-Thalassemia; Carbamates; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; India; Male; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2018 |
Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retreatment; RNA, Viral; Sequence Analysis, RNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2018 |
Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma,
Topics: Carbamates; Humans; Imidazoles; Limit of Detection; Pharmaceutical Preparations; Pyrrolidines; Reproducibility of Results; Ribavirin; Sofosbuvir; Solubility; Spectrophotometry; Valine | 2018 |
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrrolidines; Receptors, Calcitriol; Valine; Vitamin D; Young Adult | 2018 |
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
Topics: Aged; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2019 |
[Daclatasvir-sofosbuvir combination therapy for chronic hepatitis C virus infection: progress in clinical studies].
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Intervention of curcumin on oral pharmacokinetics of daclatasvir in rat: A possible risk for long-term use.
Topics: Administration, Oral; Animals; Antiviral Agents; Carbamates; Curcumin; Drug Interactions; Imidazoles; Ketoconazole; Male; Pyrrolidines; Quinidine; Rats; Rats, Wistar; Valine | 2018 |
Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine | 2018 |
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.
Topics: Antiviral Agents; Carbamates; China; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Health Expenditures; Health Resources; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Life Expectancy; Male; Markov Chains; Models, Econometric; Pyrrolidines; Quality-Adjusted Life Years; Sulfonamides; Valine | 2018 |
Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Combinations; Hepacivirus; Hepatitis C; Imidazoles; Lactones; Limit of Detection; Liquid-Liquid Extraction; Male; Models, Animal; Pyrrolidines; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Sofosbuvir; Spectrophotometry, Ultraviolet; Sulfones; Ultrasonic Waves; Valine | 2018 |
Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt.
Topics: Antiviral Agents; Carbamates; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Kidney; Liver Cirrhosis; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrrolidines; Sex Factors; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2018 |
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Topics: Animals; Antiviral Agents; Benzazepines; Biomarkers; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Mice; Protease Inhibitors; Pyrrolidines; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins; Viremia | 2018 |
GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Dogs; Drug Combinations; Drug Stability; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Imidazoles; Macrocyclic Compounds; Male; Microsomes, Liver; Mutation; Pyrrolidines; Rats, Sprague-Dawley; Serine Proteases; Serine Proteinase Inhibitors; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2018 |
Direct-acting antiviral drugs are triggers for psoriasis: report of three cases.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Psoriasis; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Symptom Flare Up; Valine | 2018 |
Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Isoquinolines; Male; Middle Aged; Pyrrolidines; Recurrence; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2018 |
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Male; Middle Aged; Pharmacovigilance; Prospective Studies; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Valine | 2018 |
Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
Topics: Administration, Oral; Adult; Carbamates; Case-Control Studies; Drug Combinations; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2020 |
Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method.
Topics: Benzimidazoles; Carbamates; Fluorenes; Healthy Volunteers; Humans; Imidazoles; Molecular Structure; Pyrrolidines; Spectrometry, Fluorescence; Tablets; Valine | 2018 |
Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations.
Topics: Benzimidazoles; Carbamates; Chromatography, Thin Layer; Drug Compounding; Fluorenes; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2018 |
Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Pyrrolidines; Sulfonamides; Valine | 2018 |
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Polymorphism, Genetic; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: Application to human plasma and stability study.
Topics: Antiviral Agents; Carbamates; Cetrimonium; Drug Stability; Humans; Imidazoles; Limit of Detection; Linear Models; Micelles; Pyrrolidines; Reproducibility of Results; Spectrometry, Fluorescence; Valine | 2019 |
High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult | 2018 |
Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Carbamates; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Imidazoles; Pyrrolidines; Sequence Alignment; Valine; Viral Nonstructural Proteins; Virus Replication | 2018 |
HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2018 |
Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine; Young Adult | 2018 |
A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Hepatitis C; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Valine | 2019 |
Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Topics: Aged; Antiviral Agents; Carbamates; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Isoquinolines; Liver Transplantation; Living Donors; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Sulfonamides; Tacrolimus; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sulfonamides; Valine | 2018 |
Visualisation and analysis of hepatitis C virus non-structural proteins using super-resolution microscopy.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microscopy; Pyrrolidines; RNA, Viral; Valine; Viral Nonstructural Proteins; Virus Replication | 2018 |
Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Male; Program Evaluation; Public Health; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Biomarkers; Carbamates; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Prothrombin Time; Pyrrolidines; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine | 2019 |
Association of IL-1β, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; Drug Therapy, Combination; Egypt; Estrogen Receptor alpha; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Infections; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Liver Cirrhosis; Polymorphism, Genetic; Pyrrolidines; Sofosbuvir; Valine | 2018 |
Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Topics: Antiviral Agents; Carbamates; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Registries; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Topics: Adult; Antiviral Agents; Asian People; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Valine | 2019 |
Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
Topics: Adult; Aged; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Delivery of Health Care; Female; Fluorenes; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Telemedicine; Treatment Outcome; Valine | 2020 |
Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Agammaglobulinemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genetic Diseases, X-Linked; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunoglobulin G; Immunoglobulins, Intravenous; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2019 |
A Patient of Chronic Hepatitis C Complicated by Thalassemia Major and Chronic Osteomyelitis: A Therapeutic Challenge for a Clinician.
Topics: Adolescent; Antiviral Agents; beta-Thalassemia; Blood Transfusion; Carbamates; Chronic Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Osteomyelitis; Pyrrolidines; Sofosbuvir; Valine | 2018 |
Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti-hepatitis C drug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids.
Topics: Antiviral Agents; Body Fluids; Carbamates; Chromatography, High Pressure Liquid; Fluorescence; Humans; Imidazoles; Pyrrolidines; Spectrometry, Fluorescence; Tablets; Valine | 2018 |
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Markov Chains; Pyrrolidines; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate; Valine | 2019 |
NS5A Promotes Constitutive Degradation of IP3R3 to Counteract Apoptosis Induced by Hepatitis C Virus.
Topics: Animals; Apoptosis; Carbamates; Cell Line; F-Box Proteins; Hepacivirus; Hepatitis C; Humans; Imidazoles; Inositol 1,4,5-Trisphosphate Receptors; Leucine; Protein Multimerization; Proteolysis; Pyrrolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2018 |
Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Valine; Viral Load | 2019 |
Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Combined Modality Therapy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pilot Projects; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins | 2019 |
Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Female; gamma-Globulins; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Imidazoles; Liver; Liver Cirrhosis; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Serum Albumin; Sofosbuvir; Valine; Viral Load | 2019 |
Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunocompromised Host; Isoquinolines; Liver Transplantation; Living Donors; Middle Aged; Pyrrolidines; Recurrence; Sulfonamides; Valine | 2018 |
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Transplant Recipients; Uridine; Valine | 2019 |
Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Pyrrolidines; Recurrence; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA; Sofosbuvir; Sulfonamides; Valine | 2019 |
Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quality of Life; Simeprevir; Socioeconomic Factors; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Stability-indicating micellar enhanced spectro-fluorometric determination of Daclatasvir in its tablet and spiked human plasma.
Topics: Calibration; Carbamates; Drug Stability; Humans; Hydrogen-Ion Concentration; Imidazoles; Limit of Detection; Micelles; Pyrrolidines; Reproducibility of Results; Sensitivity and Specificity; Sodium Dodecyl Sulfate; Solvents; Spectrometry, Fluorescence; Surface-Active Agents; Tablets; Time Factors; Valine | 2019 |
Hepatitis C virus NS5A inhibitor daclatasvir allosterically impairs NS4B-involved protein-protein interactions within the viral replicase and disrupts the replicase quaternary structure in a replicase assembly surrogate system.
Topics: Antiviral Agents; Carbamates; Cell Line; Humans; Imidazoles; Protein Binding; Protein Conformation; Protein Interaction Maps; Pyrrolidines; RNA-Dependent RNA Polymerase; Valine; Viral Nonstructural Proteins | 2019 |
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2019 |
Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects.
Topics: Antiviral Agents; Asian People; Benzazepines; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Models, Biological; Pyrrolidines; Sulfonamides; Valine | 2019 |
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
Topics: Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Dialysis; Retreatment; Sulfonamides; Treatment Failure; Valine | 2019 |
Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Humans; Imidazoles; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Topics: Adult; Aged; Alanine Transaminase; Algorithms; Benzazepines; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Sulfonamides; Valine | 2019 |
Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Indonesia; Male; Medically Underserved Area; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult | 2018 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Topics: Aged; Animals; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cell Line; Chimera; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Guanosine Monophosphate; Hepacivirus; Hepatitis C; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Mice; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sequence Deletion; Serine Proteases; Simeprevir; Valine; Viral Nonstructural Proteins | 2019 |
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine | 2019 |
Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Psoriasis; Pyrrolidines; Quality of Life; Sofosbuvir; Treatment Outcome; Valine; Viral Load; Young Adult | 2019 |
Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Carbamates; Cholesterol; Dexamethasone; Drug Combinations; Dyslipidemias; Female; Framycetin; Genotype; Glycated Hemoglobin; Gramicidin; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quality of Life; Valine; Young Adult | 2019 |
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine | 2019 |
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pakistan; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2019 |
Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy.
Topics: Antiviral Agents; Carbamates; Community Pharmacy Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Medication Adherence; Middle Aged; Pharmacists; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Cells, Cultured; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Oleanolic Acid; Pyrrolidines; Saponins; Valine; Viral Nonstructural Proteins; Virus Replication | 2019 |
Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissoluti
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Imidazoles; Limit of Detection; Pyrrolidines; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Sofosbuvir; Solubility; Valine | 2019 |
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine.
Topics: Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Stability; Fluoxetine; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Pyrrolidines; Reproducibility of Results; Valine | 2019 |
A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study.
Topics: Carbamates; Chromatography, Liquid; Female; Humans; Imidazoles; Limit of Detection; Linear Models; Male; Middle Aged; Pyrrolidines; Reproducibility of Results; Retrospective Studies; Simeprevir; Sofosbuvir; Tandem Mass Spectrometry; Valine | 2019 |
Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Topics: Carbamates; Chromatography, High Pressure Liquid; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Ribavirin; Sofosbuvir; Valine | 2019 |
A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.
Topics: Antiviral Agents; Carbamates; Cell Death; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Intracellular Space; Pyrrolidines; Recurrence; Simeprevir; Sofosbuvir; Valine; Virus Replication | 2019 |
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Myanmar; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Brazil; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2019 |
Forced Oxidative Degradation Pathways of the Imidazole Moiety of Daclatasvir.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Hydrochloric Acid; Hydrogen Peroxide; Hydrolysis; Imidazoles; Mass Spectrometry; Oxidation-Reduction; Photolysis; Pyrrolidines; Valine | 2019 |
Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Topics: Antiviral Agents; Blood Glucose; Carbamates; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Egypt; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Risk Factors; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy.
Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis.
Topics: Carbamates; Chromatography, Liquid; Humans; Imidazoles; Indicator Dilution Techniques; Isotope Labeling; Liquid-Liquid Extraction; Pyrrolidines; Tandem Mass Spectrometry; Valine | 2019 |
Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Carbamates; Child; Child Development; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
Topics: Aged; Antiviral Agents; Asthma; Carbamates; Coinfection; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; Hepatitis E; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tenofovir; Treatment Outcome; Valine; Viral Load | 2020 |
Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Male; Middle Aged; Pakistan; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2019 |
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Failure; Male; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2019 |
Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Carbamates; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Pyrrolidines; Sulfonamides; Up-Regulation; Valine | 2019 |
Design of bile-based vesicles (BBVs) for hepatocytes specific delivery of Daclatasvir: Comparison of ex-vivo transenterocytic transport, in-vitro protein adsorption resistance and HepG2 cellular uptake of charged and β-sitosterol decorated vesicles.
Topics: Adsorption; Animals; Antiviral Agents; Biological Transport; Carbamates; Cholesterol; Deoxycholic Acid; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Hepatocytes; Humans; Imidazoles; Liposomes; Liver; Male; Particle Size; Phosphatidylcholines; Pyrrolidines; Rats; Rats, Wistar; Sitosterols; Valine | 2019 |
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tuberculosis; Valine | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2019 |
[Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Transforming Growth Factor beta; Treatment Outcome; Valine; Viral Load | 2019 |
Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir.
Topics: Aged; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine; Viral Load | 2020 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine | 2019 |
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2019 |
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Topics: Aged; Animals; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Caco-2 Cells; Carbamates; Drug Interactions; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Imidazoles; Intestines; Lopinavir; Male; Maraviroc; Middle Aged; Pyrrolidines; Rats; Rats, Wistar; Ritonavir; Saquinavir; Valine; Zidovudine | 2019 |
Superiority of DEAE-Dx-Stabilized Cationic Bile-Based Vesicles over Conventional Vesicles for Enhanced Hepatic Delivery of Daclatasvir.
Topics: Animals; Bile Acids and Salts; Biological Availability; Carbamates; Cations; DEAE-Dextran; Drug Carriers; Drug Delivery Systems; Imidazoles; Intestinal Mucosa; Liposomes; Liver; Male; Mice; Permeability; Pyrrolidines; Rats; Rats, Wistar; Tissue Distribution; Valine | 2019 |
Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Topics: Adult; Aged; Antiviral Agents; Bangladesh; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Pyrrolidines; RNA, Viral; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2019 |
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Random Allocation; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine | 2020 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Chemometrically Assisted Development of Ultra-High-Performance Liquid Chromatography Method for the Simultaneous Quantification of Sofosbuvir, Daclatasvir and Ledipasvir in Pharmaceutical Dosage Forms.
Topics: Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tablets; Valine | 2020 |
Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir.
Topics: Antiviral Agents; Benzazepines; Carbamates; Chromatography, Liquid; Cytochrome P-450 CYP3A; Genetic Variation; Genotype; Humans; Imidazoles; Indoles; Isoquinolines; Liver; Microsomes, Liver; Pyrrolidines; Recombinant Proteins; Sulfonamides; Tandem Mass Spectrometry; Valine | 2020 |
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Topics: Antiviral Agents; Carbamates; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Optimization of a liquid chromatography method for the analysis of related substances in daclatasvir tablets using design of experiments integrated with the steepest ascent method and Monte Carlo simulation.
Topics: Carbamates; Chromatography, Liquid; Drug Contamination; Hydrogen-Ion Concentration; Imidazoles; Monte Carlo Method; Pyrrolidines; Reproducibility of Results; Research Design; Tablets; Temperature; Valine | 2020 |
Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Mutation; Pyrrolidines; Sofosbuvir; Treatment Failure; Valine; Viral Nonstructural Proteins | 2019 |
Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Brazil; Carbamates; Drug Therapy, Combination; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2019 |
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin.
Topics: Carbamates; Drug Therapy, Combination; Egypt; Endpoint Determination; Gene Frequency; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Logistic Models; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Daclatasvir and Sofosbuvir Mitigate Hepatic Fibrosis Through Downregulation of TNF-α / NF-κB Signaling Pathway.
Topics: Animals; Carbamates; Carbon Tetrachloride; Disease Progression; Down-Regulation; Hepatic Stellate Cells; Imidazoles; Liver; Liver Cirrhosis; Male; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Rats, Wistar; Sofosbuvir; Tumor Necrosis Factor-alpha; Valine | 2020 |
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Italy; Male; Middle Aged; Pyrrolidines; Regression Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2020 |
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Pyrrolidines; Renal Dialysis; Renal Insufficiency; Safety; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney; Lipocalin-2; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2020 |
Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Renal Insufficiency, Chronic; Sulfonamides; Valine | 2020 |
Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals
.
Topics: Antiviral Agents; Carbamates; Cote d'Ivoire; Cross-Sectional Studies; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hospitals, University; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
Topics: Adiponectin; Aged; Alanine Transaminase; Benzimidazoles; Blood Glucose; Carbamates; Cholesterol; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Insulin; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2020 |
Screening and Treatment Program to Eliminate Hepatitis C in Egypt.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Egypt; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Male; Mass Screening; Middle Aged; Pyrrolidines; Seroepidemiologic Studies; Sofosbuvir; Valine; Young Adult | 2020 |
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Valine | 2020 |
Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Sofosbuvir; Treatment Outcome; Valine | 2020 |
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Topics: Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine | 2020 |
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Prospective Studies; Pyrrolidines; Sofosbuvir; Valine | 2020 |
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Radiofrequency Ablation; Recurrence; Sulfonamides; Valine; Viral Load | 2020 |
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Topics: Africa South of the Sahara; Antiviral Agents; Asia, Eastern; Benzimidazoles; Benzofurans; Carbamates; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; RNA-Dependent RNA Polymerase; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2020 |
Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
Topics: Aged; Antibodies, Antinuclear; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2020 |
Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Carbamates; Case-Control Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2020 |
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Topics: Adult; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Carbamates; Drug Combinations; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Glycosylation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; ROC Curve; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir.
Topics: Antiviral Agents; Brazil; Carbamates; Cognition; Drug Therapy, Combination; Genotype; Hepacivirus; Humans; Imidazoles; Male; Prospective Studies; Pyrrolidines; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; France; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
Topics: Aged; Antiviral Agents; Carbamates; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Risk; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Triglycerides; Valine | 2020 |
Ukrainian health authorities adopt hepatitis C project.
Topics: Antiviral Agents; Carbamates; Delivery of Health Care; Drug Therapy, Combination; Drugs, Generic; Health Plan Implementation; Hepacivirus; Hepatitis C; Humans; Imidazoles; Physicians; Pyrrolidines; Sofosbuvir; Ukraine; Valine | 2020 |
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrrolidines; Risk Factors; Sulfonamides; Sustained Virologic Response; Valine | 2020 |
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Unusual complexation behavior between daclatasvir and γ-Cyclodextrin. A multiplatform study.
Topics: Carbamates; Electrophoresis, Capillary; gamma-Cyclodextrins; Imidazoles; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Conformation; Pyrrolidines; Stereoisomerism; Valine | 2020 |
Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
Topics: Amides; Antiviral Agents; Benzofurans; Biomarkers; Carbamates; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Quinoxalines; Sulfonamides; Valine | 2021 |
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.
Topics: Animals; Antiviral Agents; Carbamates; Disease Models, Animal; Dogs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Mice; Pyrrolidines; Rats; Rats, Sprague-Dawley; Valine; Viral Envelope Proteins; Virus Internalization | 2020 |
Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidines; Sofosbuvir; Uridine; Valine | 2020 |
The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
Topics: Adult; Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lipid Metabolism; Lipids; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Valine | 2021 |
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2021 |
Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2020 |
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Topics: Antiviral Agents; Brazil; Carbamates; Cell Line, Tumor; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Mutation; Pyrrolidines; Recurrence; Sofosbuvir; Valine; Viral Nonstructural Proteins; Virus Replication | 2021 |
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Failure; Valine | 2021 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine | 2021 |
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Seropositivity; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; New Zealand; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2020 |
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2020 |
Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.
Topics: Antiviral Agents; Carbamates; China; COVID-19; Humans; Imidazoles; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Valine | 2021 |
Improved spectral resolution for the rapid simultaneous spectrophotometric determination of sofosbuvir and daclatasvir as anti hepatitis C virus drugs in pharmaceutical formulation and biological fluid using continuous wavelet and derivative transform.
Topics: Carbamates; Drug Compounding; Hepacivirus; Humans; Imidazoles; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Spectrophotometry; Valine | 2021 |
Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Retreatment; Sulfonamides; Valine | 2021 |
Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
Topics: Adult; Antiviral Agents; Biomarkers; Blood Chemical Analysis; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Host Microbial Interactions; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Real-Time Polymerase Chain Reaction; RNA, Viral; ROC Curve; Sofosbuvir; Valine; Viral Load | 2021 |
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Mass Screening; Middle Aged; Pilot Projects; Program Evaluation; Public Health; Pyrrolidines; Rural Health Services; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2021 |
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Black People; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Young Adult | 2021 |
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Topics: Animals; Antiviral Agents; Carbamates; Chlorocebus aethiops; COVID-19; Humans; Imidazoles; Pharmaceutical Preparations; Pyrrolidines; RNA, Viral; SARS-CoV-2; Sofosbuvir; Valine; Vero Cells | 2021 |
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Applying different spectroscopic techniques for the selective determination of daclatasvir using merbromin as a probe: Applications on pharmaceutical analysis.
Topics: Carbamates; Imidazoles; Merbromin; Pyrrolidines; Sofosbuvir; Spectrometry, Fluorescence; Tablets; Valine | 2021 |
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.
Topics: Adverse Drug Reaction Reporting Systems; Carbamates; Chemical and Drug Induced Liver Injury; Databases, Factual; Forecasting; Humans; Imidazoles; Isoquinolines; Liver Neoplasms; Protease Inhibitors; Pyrrolidines; Receptors, Calcitriol; Receptors, Estrogen; Sulfonamides; United States; United States Food and Drug Administration; Valine | 2021 |
Development of a deep eutectic solvent-based ultrasound-assisted homogenous liquid-liquid microextraction method for simultaneous extraction of daclatasvir and sofosbuvir from urine samples.
Topics: Carbamates; Imidazoles; Limit of Detection; Liquid Phase Microextraction; Pyrrolidines; Sofosbuvir; Solvents; Valine | 2021 |
Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Eligibility Determination; Female; Frailty; Hepatitis C; Humans; Imidazoles; Insurance, Long-Term Care; Isoquinolines; Japan; Male; Pyrrolidines; Sulfonamides; Valine | 2021 |
Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Child; Dose-Response Relationship, Drug; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2021 |
HPLC-UV and TLC-Densitometry Methods for Simultaneous Determination of Sofosbuvir and Daclatasvir: Application to Darvoni® Tablet.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Densitometry; Imidazoles; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tablets; Valine | 2022 |
Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; COVID-19 Drug Treatment; DNA-Directed RNA Polymerases; HEK293 Cells; Hepacivirus; Humans; Imidazoles; Isoquinolines; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Sulfonamides; Valine; Vero Cells; Viral Nonstructural Proteins; Viral Protease Inhibitors; Virus Replication | 2021 |
Liver Targeting of Daclatasvir via Tailoring Sterically Stabilized Bilosomes: Fabrication, Comparative In Vitro/In Vivo Appraisal and Biodistribution Studies.
Topics: Antiviral Agents; Carbamates; Drug Carriers; Drug Delivery Systems; Hepatitis C, Chronic; Humans; Imidazoles; Particle Size; Pyrrolidines; Tissue Distribution; Valine | 2021 |
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2021 |
RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Hepatitis C; Imidazoles; Limit of Detection; Pyrrolidines; Reproducibility of Results; Tablets; Valine | 2021 |
Three Smart and Original Spectrophotometric Data Processing Ratio Techniques for Resolving the Partial Overlapped Spectra of the Binary Antiviral Mixture Daclatasvir/Sofosbuvir: Application to Combined Dosage Form Darvoni® Tablets.
Topics: Antiviral Agents; Carbamates; Imidazoles; Pyrrolidines; Sofosbuvir; Spectrophotometry; Tablets; Valine | 2022 |
Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Topics: Antiviral Agents; Area Under Curve; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Sofosbuvir; Valine | 2022 |
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interleukin-10; Liver Cirrhosis; Liver Neoplasms; Lymphadenitis; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Splenomegaly; Valine | 2021 |
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization | 2021 |
Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Valine | 2021 |
Structural characterization of methyl-β-cyclodextrins by high-performance liquid chromatography and nuclear magnetic resonance spectroscopy and effect of their isomeric composition on the capillary electrophoresis enantioseparation of daclatasvir.
Topics: beta-Cyclodextrins; Carbamates; Chromatography, High Pressure Liquid; Cyclodextrins; Electrophoresis, Capillary; Imidazoles; Magnetic Resonance Spectroscopy; Pyrrolidines; Stereoisomerism; Valine | 2022 |
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferons; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Seoul; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2022 |
Influence of piperine and omeprazole on the regional absorption of Daclatasvir from rabbit intestine.
Topics: Alkaloids; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodioxoles; Carbamates; Ileum; Imidazoles; Intestinal Absorption; Intestines; Jejunum; Omeprazole; Piperidines; Polyunsaturated Alkamides; Pyrrolidines; Rabbits; Valine | 2022 |
Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450.
Topics: Administration, Oral; Animals; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Imidazoles; Pyrrolidines; Rats; Rhodamine 123; Valine | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2022 |